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Abstract 
Thrombin-activatable fibrinolysis inhibitor (TAFI) is a molecular link between 
fibrinolysis and coagulation. TAFI gets activated either by thrombin, thrombin-
thrombomodulin complex, or plasmin. Once activated, TAFIa removes carboxyl-terminal 
lysines from partially degraded fibrin, thus attenuating fibrinolysis. It has been previously 
reported that heparin accelerates plasmin-mediated activation of TAFI and increases 
thermal stability of TAFIa. In the present study we set out to identify heparin binding 
sites on TAFI. We constructed TAFI variants that contained mutations in the regions 
proposed to participate in the interaction with heparin. We identified several variants that 
showed impaired binding to heparin. Of these, K211Q/K212Q, R320A/K324A and 
K306A showed reduced acceleration by heparin of plasmin-mediated activation, and 
K327A, K327A/R330A, and R320A/K324A showed reduced stabilization of TAFIa by 
heparin. R320A/K324A bound very poorly to heparin, and hence might represent a useful 
variant with which to study the importance of glycosaminoglycans in regulating TAFI 
function.  
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Chapter 1 
Introduction 
 
1.1 Haemostasis  
Maintaining the balance between the processes of coagulation and fibrinolysis is 
essential for proper haemostatic response. Once damage to a blood vessel occurs, a 
haemostatic response is initiated that involves soluble plasma proteins, tissue 
components, and receptors on platelets [1, 2]. This response is tightly regulated by the 
opposing coagulation and fibrinolytic cascades (Figure 1-1). The coagulation cascade is 
responsible for the formation of an insoluble fibrin clot at an injury site, while the 
fibrinolytic cascade degrades the fibrin clot [1].  Any imbalances in the regulation of 
these cascades can lead to excessive clot formation, which can lead to a heart attack or a 
stroke, or inadequate clot formation, which can result in bleeding disorders such as 
haemophilia [3]. If the two cascades are regulated properly, the haemostatic response is 
localized to the site of the injury, due to the involvement of the above mentioned plasma 
proteins, and cellular components. 
The primary response to a vascular injury, which results in the exposure of blood 
to subendothelial tissue, is initiated with the formation of a platelet plug. Inert platelets 
circulate in close contact with the endothelium, but do not adhere to the endothelial cells 
[4]. However, upon injury to the endothelium, platelets come into contact with 
extracellular matrix components resulting in platelet activation and aggregation, leading 
to the formation of a platelet plug [5]. Initially, the interaction of platelets with the 
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extracellular matrix is mediated through the platelet von Willerbrand Factor (vWF) 
receptor Glycoprotein IB/V/IX  [6] and collagen receptor Glycoprotein VI [7]. However, 
this interaction alone is insufficient to allow adhesion and instead facilitates intracellular 
signalling which activates integrins αIIb β3 and α2 β1 [7]. These integrins interact with the 
extracellular matrix to facilitate firm adhesion of platelets to the wall of an injured vessel 
resulting in the formation of a platelet monolayer. More platelets are rectuited to the 
injury site by a variety of mediators that are synthesized once platelets adhere, and limited 
activation of platelets takes place. These mediators are adenosine diphosphate (ADP), 
adenosine triphosphate (ATP), thromboxane A2, and thrombin. Thrombin is produced on 
the surface of activated platelets, while, ADP, ATP and thromboxane A2 are released 
from activated platelets [5]. Upon activation platelets change morphology. Cytoskeletal 
reorganization and secretion from storage granules takes place [8,9].  Among the secreted 
granule components are calcium ions, which are released into the cytoplasm, as well as 
vWF, and growth factors, which are released into the extracellular space. Another 
morphological change that takes place once the platelets are activated is the exposure of 
an ionic phospholipid, phosphatidylserine [9,10].  Phosphatidylserine provides a surface 
for the assembly of the enzymes and cofactors of the coagulation cascade to form 
functional complexes [9]. The secondary response to a vascular injury is the initiation of 
the coagulation cascade. Tissue Factor (TF) is a transmembrane protein that is expressed 
by various cells of the vascular wall, however, under normal conditions does not come 
into contact with blood [11]. Upon a vascular injury, TF is exposed to flowing blood and 
forms a complex with plasma protein factor VIIa (FVIIa). TF-FVIIa complex activates 
circulating factors IX and X into IXa and Xa respectively [11].FXa and its activated 
cofactor Va (FVa) form a complex on the activated platelet surface with the aid of the 
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aforementioned negatively charged exposed phospholipids. FXa-FVa complex on the 
platelet surface is termed the ‘prothrombinase’ complex, as it activates prothrombin to 
thrombin [12]. The majority of the circulating FV is activated by the thrombin that is 
generated in the initial stages of the coagulation process. TF-dependant coagulation 
pathway is often termed ‘extrinsic’ [2]. However, there is another pathway that can result 
in the activation of prothrombin to thrombin. This pathway is termed ‘intrinsic’, and, in 
vitro, can be initiated by the factor XII (FXII), high molecular weight kininogen, and 
prekallikrein, which results in the activated FXII (FXIIa), which in turn activates FXI, 
followed by activation of FIX [2].  However the current concept is that FXII, high 
molecular weight kininogen, and prekallikrein do not play a role in the activation of the 
intrinsic pathway in vivo but, rather, limited activation of FXI by thrombin initiates the 
pathway through activation of FIX [13,14]. FIXa forms a complex with thrombin-
activated FVIIIa that is termed the ‘tenase’ complex [2]. The function of this complex is 
to convert FX to FXa. The assembly of the ‘tenase’ complex, just like the assembly of the 
‘prothrombinase’ complex occurs on the negatively charged phospholipid surface of the 
activated platelets [2]. The ‘extrinsic’ pathway is the main activator of the coagulation 
cascade, while the ‘intrinsic’ pathway allows for amplification of the amount of thrombin 
generated [15]. In addition to providing a negatively charged surface for the assembly of 
the coagulation factors, activated platelets expose Glycoprotein IIb/IIIa receptors that can 
efficiently bind the soluble plasma protein fibrinogen. Thrombin generated from both 
‘extrinsic’ and ‘intrinsic ‘cascades cleaves platelet-bound fibrinogen to form fibrin to 
further stabilize the platelet plug [16].  Thrombin then cleaves circulating fibrinogen to  
4 
 
Figure 1-1. The balance between the coagulation and fibrinolytic cascades. The 
extrinsic pathway of coagulation produces a small amount of thrombin that promotes 
fibrin formation and the activation of the intrinsic pathway. The large amount of thrombin 
produced by the intrinsic pathway consolidates the clot, in part through activation of 
TAFI. In complex with thrombomodulin, thrombin no longer recognizes fibrinogen as a 
substrate but its ability to activate protein C and TAFI is enhanced by three orders of 
magnitude. Fibrin dissolution is accomplished by plasmin, which is formed by cleavage 
of plasminogen by tPA with fibrin as an essential cofactor. Limited digestion of fibrin 
leads to a form of fibrin that contains exposed carboxyl-terminal lysines. This form of 
fibrin is a several-fold more effective cofactor for plasminogen activation. TAFIa 
attenuates plasminogen activation by removing the carboxyl-terminal lysines, thereby 
yielding a form of fibrin with no cofactor activity.  
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create a meshwork to form a fibrin plug over the aggregated platelets [17]. Furthermore, 
generated thrombin activates FXIII, a transglutaminase, that cross-links fibrin monomers 
to stabilize the fibrin clot [16].     
Uncontrolled blood coagulation is dangerous, and is controlled by anticoagulant 
pathways. The serine protease inhibitor (SERPIN) antithrombin (AT) downregulates clot 
formation by inhibiting Factors Xa, XIa, and thrombin [18,19]. AT is much more efficient 
at binding and inhibiting free circulating enzymes, then the enzymes that are assembled in 
the ‘tenase’ or ‘prothrombinase’ complexes on the activated platelet surface [20] or fibrin, 
in the case of thrombin [21]. The preferential affinity of AT to the free enzymes assists 
with limiting the coagulation reactions to the sites of vascular injury. The inhibitory 
function of AT is highly stimulated by heparin [22,23]. Because of this function, heparin 
is used as anticoagulant therapy. The activated protein C pathway is another anticoagulant 
pathway which controls coagulation. Activated protein C functions by inactivating the 
glycoprotein cofactors FVIIIa, and FVa [24].   
To maintain proper haemostasis once the healing to the injured vessel has 
occurred, the fibrinolytic system is responsible for dissolution of the clot.  Plasmin serves 
as a central enzyme of the fibrinolytic cascade. Plasmin is a serine protease that cleaves 
fibrin to form soluble fibrin degradation products (FDPs), which ultimately leads to the 
dissolution of the clot. This protease is generated by the activation of plasminogen by 
plasminogen activators, tissue-type plasminogen activator (tPA) and urokinase-type 
plasminogen activator (uPA), with the former enzyme being more important to the lysis 
of intravascular thrombi [25]. As in the case with coagulation, enzyme inhibitors play a 
key role in controlling and localizing the fibrinolytic cascade. tPA and plasmin are bound 
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and inhibited  by plasminogen activator inhibitor (PAI-1) and α-antiplasmin respectively 
[26,27]. Plasmin promotes activation of plasminogen to form more plasmin by cleaving  
fibrin to expose carboxyl-terminal lysines [28,29]. This partially degraded form of fibrin 
possesses exposed carboxyl-terminal lysine residues and acts as a more efficient cofactor 
for tPA-mediated activation of plasminogen, by providing binding sites for both 
plasminogen and tPA [25].  Additional roles of the carboxyl-terminal lysines will be 
discussed below. 
Studies in the 1990’s defined a molecular mechanism that functionally links the 
coagulation and fibrinolytic cascades. Studies of clot lysis in vitro revealed the presence 
of a factor that was activated by the coagulation cascades and appeared to inhibit the 
fibrinolysis; accordingly, activation of protein C in the clots prevented the action of this 
factor. The factor was purified and found to be procarboxypeptidase B-related zymogen, 
and was termed thrombin activatable fibrinolysis inhibitor (TAFI) [30,31]. TAFI 
attenuates fibrinolysis by cleaving C-terminal lysine residues from partially degraded 
fibrin, yielding a form of fibrin that does not possess cofactor activity for tPA-mediated 
plasminogen activation [32,33]. 
 
1.2 TAFI 
Thrombin-Activatable fibrinolysis Inhibitor (TAFI) is a 60-kDa procarboxypeptidase B-
related glycoprotein zymogen that was originally thought to be expressed only in the 
liver, and secreted to circulate in the plasma [34]. However, recent studies have shown 
that TAFI is expressed, although in smaller amounts, in megakaryocytes, endothelial 
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cells, macrophages, and adipocytes [35-37]. The translated product consists of 423 amino 
acids, of which 22 make up a signal peptide, 92 amino acids make up an activation 
peptide, while the remaining 309-amino acids represent a catalytic domain. The signal 
peptide is cleaved before secretion from the liver [34].The theoretical molecular weight of 
TAFI zymogen is approximately 46 kDa, however, the apparent molecular weight of 
TAFI on SDS-PAGE is 60 kDa, due to N-linked glycosalation of TAFI [38,39]. TAFI 
zymogen is inactive and consists of the activation peptide, and the catalytic domain.  
TAFI becomes activated upon the cleavage at Arg92 which results in release of the 
activation peptide, and exposure of the TAFIa active site [31,40] .Proteolysis of the 
activation peptide is catalyzed by thrombin, or plasmin (Figure 1-2) [34]. However, both 
activators are relatively inefficient in cleaving the activation peptide. Thrombin, in 
complex with the endothelial cell surface cofactor thrombomodulin (TM), is 1250-fold 
more effective at activating TAFI [41]. In similar fashion, plasmin, in the presence of 
glycosaminoglycans, such as heparin, exhibits a 16-fold increase in the activation 
efficiency [43].  Previously, it has been suggested that thrombin-TM complex is the 
physiological activator of TAFI, due to the apparent efficiency in activating TAFI 
compared to thrombin. In comparison to plasmin, even in the presence of 
glycosaminoglycans, thrombin-TM complex exhibits 10-fold greater catalytic efficiency 
[43]. However, it has been shown that half-maximal effect of TAFIa on inhibition of clot 
lysis time is achieved at 1nM in vitro [41]. This represents less than 2% of the total 
concentration of TAFI in plasma. Therefore, significant inhibition of fibrinolysis can be 
achieved via activation of TAFI by thrombin, or plasmin alone, and this has certainly 
been demonstrated both in vitro and in vivo in animal models [44,45,46,47]. It is 
important to note that the contribution of these individual activators is unknown; in fact, 
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the contribution of these activators may be dependent on the location of the activation of 
TAFI, as well as the presence of vascular injury [43]. 
Vascular injury exposes glycosaminoglycans that are present in the extracellular matrix 
[48]. Therefore, plasmin-mediated activation of TAFI may be a significant contributor to  
proper clot stability at the injury site. On the other hand, if the vessel is not injured, 
thrombin-TM may play a key role in activation of TAFI, and proper fibrinolysis control 
[43,44]. 
To date, there are no known endogenous inhibitors of TAFIa. However, it has been 
shown that the intrinsic thermal instability is responsible for the inactivation  of the 
enzyme; the activity of TAFIa appears to spontaneously decay with a half-life of 8-15 
minutes [49,55]. This phenomenon has been associated with a marked structural change 
in the enzyme as assessed by measurement of the intrinsic fluorescence [50]. Crystal 
structures of TAFI have shed some light on the structural basis for the intrinsic instability 
of this enzyme. Crystal structure analysis suggests that residues 296-350 of TAFI play a 
key role in the thermal stability. Before cleavage at Arg92, the activation peptide of TAFI 
stabilizes the above mentioned region. Once cleavage occurs, the activation peptide no 
longer interacts with this region. This is followed by increase in the dynamics of this 
region and unfolding of TAFIa, yielding exposed thrombin and plasmin cleavage sites of 
TAFIa [51,52,53]. Proteolytic cleavage of activated TAFI by thrombin, or plasmin has 
also been suggested to play a critical role in regulating levels of TAFIa, since this 
cleavage yields a form of TAFIa that is inactive. Thrombin cleaves TAFIa at Arg302, 
while plasmin cleaves TAFIa at Arg302, Lys327, and Arg330 [49,53]. (Figure 1-2) 
However, it has been shown that this proteolytic cleavage by thrombin can occur only 
after thermal inactivation of TAFIa, while cleavage of TAFIa by plasmin can occur 
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before and after thermal inactivation. Proteolytic cleavage of TAFIa by plasmin is 
accelerated following thermal inactivation. This suggests that thermal inactivation is a 
primary method of regulating TAFIa levels [49,53] ; indeed, mutants of TAFI, both 
naturally occurring and those created in the 296-350 region, that alter the intrinsic 
stability of TAFIa, correspondingly alter the antifibrinolytic potential of the enzyme 
[54,55]. The importance of proteolytic cleavage of TAFIa, as a way of regulating TAFIa 
levels, remains unknown [49,53].  In vitro clot lysis studies have shown that TAFIa 
exhibits the antifibrinolytic effect in a threshold-dependant manner. Like every threshold 
system, this one is also very complex, as the threshold concentration of TAFIa is 
dependent on the concentrations of other components of the pathways, such as 
plasminogen, plasminogen activator, and antiplasmin. However, as long as TAFIa 
concentration remains above a certain level, fibrinolysis is attenuated [56]. However, due 
to its intrinsic instability, and the consequential short half-life, the concentration of TAFIa 
gets progressively lower, and falls below the threshold value. Therefore increased clot 
lysis time is highly dependent on the half-life of an enzyme, which dictates the 
concentration of TAFIa [56, 57], as a more stable variant of TAFI (Ile325) exhibits 
increased antifibrinolytic potential [58]. 
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Figure 1-2. Activation of TAFI and inactivation TAFIa. TAFI consists of a pro-
domain (black), which contains four N-linked glycans, and a catalytic domain (grey). 
Cleavage at Arg92 releases the activation peptide and formation of TAFIa. TAFIa is 
thermally unstable, and undergoes a conformational change which is associated with loss 
of carboxypeptidase B activity and formations of TAFIai. This conformational change 
also exposes Arg302, Lys327 and Arg330.The figure was adapted and modified from 
ref.41. The inset shows the location of Arg92, the target of thrombin and plasmin 
cleavage. Crystallographic data are from ref. 39 (PDB # 3D66). The side chain of the P1 
arginine recognized by thrombin and plasmin is shown in red. The side chains of residues 
putatively involved in pinning Arg92 to the side of the zymogen are shown in cyan. 
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Although there are no known endogenous inhibitors of TAFIa, the role that 
several reversible inhibitors have on fibrinolytic effect of TAFIa has been studied [58]. 
Two of these inhibitors are 2-guanidinoethylmercaptosussinate (GEMSA), and potato 
tuber carboxypeptidase inhibitor (PTCI). It was found that these inhibitors of TAFIa 
exhibit a biphasic effect on the antifibrinolytic potential of TAFIa. This biphasic effect 
was found to be concentration dependant, where the clot lysis was prolonged at lower 
concentrations of the inhibitor, while enhancing clot lysis at higher concentrations of the 
inhibitor. This effect is thought to be due to the dynamic equilibrium of TAFIa bound to 
the inhibitor, and free TAFIa. When TAFIa is not bound to the inhibitor, it displays 
carboxypeptidase activity [58].  However, at body temperature, it undergoes spontaneous 
thermal inactivation rapidly [49]. On the other hand, TAFIa that is bound to the inhibitor 
does not display carboxypeptidase activity, but the half-life of TAFIa is increased when it 
is bound to the reversible inhibitor [40]. Since there is a dynamic equilibrium between 
bound and unbound TAFIa, as unbound TAFIa becomes inactivated, the dynamic 
equilibrium shifts to replenish the pool of unbound TAFIa as the reversible inhibitor is 
released. This observation would only remain true when the concentration of the 
reversible inhibitor is low enough, or the concentration of TAFIa is high enough, to 
sustain a pool of TAFIa that is not bound to the inhibitor. Since it has been shown that 
thermal stability plays a great role in the antifibrinolytic activity, extension of the half-life 
of TAFIa, and therefore clot-lysis time via reversible inhibitors can be used 
therapeutically [58]. However, since the biphasic effect is greatly dependant on the 
concentrations of TAFIa and the inhibitor in question, the effect that various 
concentrations of the inhibitor have on each individual becomes more complicated. 
Therefore, the use of these reversible inhibitors as therapeutic agents may be problematic 
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[58].  A number of studies on have been done to evaluate whether administration of the 
reversible TAFIa inhibitor alone improves endogenous thrombolysis. However, to date, in 
vivo results for various synthetic and naturally occurring inhibitors have been 
contradictory, as the efficiency of the inhibitor was found to be dependent on a number of 
factors, such as: the type of the thrombosis model, the studied animal species, the type of 
inhibitor, and whether the administration of the inhibitor is before or after the thrombus 
formation [59]. Although the reason for such great variability in data is unknown, there is 
a possibility that the biphasic effect of TAFIa inhibitors may contribute to that variability. 
One of the TAFIa inhibitors, AZD9684 was administered to pulmonary embolism 
patients in a phase II study [59]. However, according to the report by Astra Zeneca, the 
company that was developing this inhibitor, it is now discontinued (60).  
As mentioned above, plasmin is a central enzyme of the fibrinolytic cascade. 
Plasmin digests fibrin, which structures a fibrin clot, into soluble FDPs. This results in the 
dissolution of a fibrin clot [25,59]. Fibrin provides binding sites for t-PA and 
plasminogen, and thus accelerates activation of plasminogen by 500-fold. The formation 
of this complex also restricts the activation of plasminogen to the site of a fibrin clot [62]. 
Initial plasmin cleavage of fibrin, however, cleaves fibrin to yield fibrin with exposed C-
terminal lysines. These lysines bind t-PA and plasminogen, yielding a form of fibrin that 
acts as a better cofactor for t-PA-mediated plasminogen activation. In fact the increased 
efficiency of the partially degraded fibrin as a cofactor for plasminogen activation is 
approximately 3-fold [32,63]. It should also be noted that plasmin can cleave 
plasminogen from the initial Glu-plasminogen form to Lys-plasminogen form, which is 
more readily activated by t-PA to form Lys-plasmin [62,64]. Once activated, TAFI 
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exhibits carboxypeptidase activity on the partially degraded fibrin, which possesses 
carboxyl-terminal lysines, by cleaving these residues from the partially degraded fibrin. 
TAFIa attenuates fibrinolysis through a number of mechanism, however, all based on its 
ability to cleave carboxyl-terminal lysines from partially degraded fibrin. As mentioned 
above, partially degraded fibrin exhibits greater cofactor activity for tPA-mediated 
plasminogen activation. TAFIa thus reduces the cofactor activity of the partially degraded 
fibrin, and therefore attenuates fibrinolysis [32]. In the same manner, TAFIa reduces the 
conversion of Glu-plasminogen to Lys-plasminogen by removing carboxyl-terminal 
lysine residues from partially-degraded fibrin, which also downregulates fibrinolysis [32]. 
Both downregulation mechanisms result in lower plasminogen activation, and therefore 
lower plasmin concentration. As mentioned previously, one of the inhibitors that 
regulates fibrinolysis is α2-antiplasmin, which binds plasmin irreversibly, and therefore 
inhibits the function of plasmin [27]. Plasmin, however, has the ability to bind to the 
lysine residues of the partially degraded fibrin. When bound to fibrin, plasmin is 
protected from the inhibition by α2-antiplasmin [65]. Once TAFIa cleaves the carboxyl-
terminal lysines from partially degraded fibrin, plasmin can no longer bind to the fibrin, 
and therefore is more readily inhibited by α2-antiplasmin [66]. This results in lower 
localized plasmin concentration, which in turn corresponds to attenuation of clot lysis.  
 
1.3 Plasmin 
As previously mentioned, plasmin is a central enzyme of the fibrinolytic cascade, 
which is produced via activation of the proenzyme plasminogen. Plasmin is a serine 
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protease that cleaves fibrin to form fibrin degradation products, which ultimately leads to 
the dissolution of the clot [67-69]. Plasminogen is a single-chain glycoprotein that 
circulates in plasma at an approximate concentration of 2 µM. Plasminogen activation to 
plasmin occurs through cleavage of Arg561-Val562 by tPA or uPA [69-71].  Plasmin is a 
two-chain serine protease, linked by disulfide bonds, with an approximate molecular 
weight 85 kDa, the heavy chain and light chain being 60 kDa and 25 kDa respectively. 
The heavy chain of plasmin is composed of five kringle domains, which are involved in 
the interaction of plasmin with other proteins, including fibrin, and the inhibitor of 
plasmin, α2-antiplasmin [69]. Although plasminogen activation is possible without being 
bound to fibrin, once tPA and plasminogen are both bound to partially degraded fibrin, 
via carboxyl-terminal lysines, plasminogen activation is greatly accelerated. The 
carboxyl-terminal lysines are removed by TAFIa, thus reducing plasminogen activation, 
and reducing plasmin concentration [69, 25]. Although plasmin is considered to be the 
main enzyme of the fibrinolytic cascade, it can also act as an antifibrinolytic enzyme, 
through activation of TAFI [34].  Plasmin activates TAFI to form TAFIa, which 
ultimately attenuates fibrinolysis [32]. It has been reported that plasmin substrate 
specificity has been subjected to negative selection during evolution to prevent auto-
activation of plasminogen by plasmin. Plasmin is a very poor activator of plasminogen, 
which is important to prevent short-circuiting of the fibrinolytic system through auto-
activation of plasminogen by plasmin. Optimal substrate for catalysis by plasmin contain 
a lysine or an arginine residue at the P1 position, an aromatic residue at the P2 position, 
either arginine, lysine, or serine at the P1’ position, as well as arginine, lysine, or glycine 
at the P2’ position. Plasmin does not have stringent specificity at the P3 position of the 
substrates [72]. Plasminogen, however has a proline at the P2 position which prevents 
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cleavage by plasmin [73]. Of note, TAFI has a proline at the P2 position as well, Pro91, 
which may account for the relatively inefficient activation of TAFI by plasmin 
[74].Therefore, plasmin’s role in fibrinolysis is dependent on the balance between 
activation of plasminogen, inhibition of plasmin by antiplasmin, and plasmin-mediated 
activation of TAFI [32,65]. 
 
1.4 Multifunctional Role of Glycosaminoglycans 
Glycosaminoglycans play a central role in regulating the balance between 
coagulation and fibrinolysis. Heparin is a glycosaminoglycan that is synthesized in mast 
cells and consists of alternating 14 linked residues of D-glucuronic acid and D-
glucosamine [75]. During its biosynthesis, heparin chains are attached to a core protein, 
serglycin, through serine residues. However, this peptidoglycan gets cleaved by β-
endoglucoronidase to yield a number of heparin molecules [76]. Another molecule that is 
structurally related to heparin is heparan sulphate, which also contains repeating of D-
glucuronic acid and D-glucosamine residues. Compared to heparin, however, heparan 
sulfate is less sulfonated. On average, heparin contains 2.7 sulfate groups per 
disaccharide, while heparan sulfate, contains one sulfate group per disaccharide [77]. 
Unlike heparin, heparan sulfate gets synthesized by most mammalian cells, and becomes 
incorporated into the cell surface and the extracellular matrix [78]. The molecular weight 
of heparin varies from 5kDa to 40 kDa, while the molecular weight of heparan sulphate 
varies between 5kDa to 50 kDa [77]. Due to its heterogeneity, heparin, as well as other 
glycosaminoglycans, can bind to a variety of proteins and therefore play an important role 
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in the biological function of these proteins [75,79]. The specificity of the interactions of 
glycosaminoglycans and the binding protein in question depends on the ionic interactions 
of the negatively charged sulphate with positively charged basic residues. However, it has 
also been shown that hydrogen bonds may play a role in heparin binding to proteins. 
Arginine residues exhibit tighter binding to heparin than lysine residues. This 
phenomenon is largely attributed to the stronger hydrogen bond between the guanidine 
side chain of arginine and the sulphate group of heparin, compared to the ammonium side 
chain of lysine [80].  
Heparin accelerates inhibition of a number of proteinases of the blood coagulation 
system by proteinase inhibitors antithrombin and heparin cofactor II. Antithrombin 
inhibits thrombin, as well as Factors IXa, and Xa, while heparin cofactor II inhibits 
thrombin only [22, 23]. It has been previously reported that heparin first binds to the 
inhibitor, either antithrombin or heparin cofactor II, forming a complex. The formation of 
this complex induces a conformational change, which yields a more rapid reaction of the 
inhibitor and the proteinase in question. Heparin accelerates inhibition of thrombin by 
antithrombin by a factor of 2000 [81,22]. However, there is a minimum length 
requirement for heparin to bind to certain proteins, and therefore exhibit its effect on 
inhibition. In the case of thrombin inhibition by antithrombin, heparin that is made up of 
at least 5 saccharide units, with a 3-O-sulfo group on an internal glucosamine residue, is 
specifically required for high affinity to antithrombin [82]. However, this pentasaccharide 
is a minimal requirement for binding. There is also a minimal length requirement, of at 
least 16 saccharides, needed to accelerate the inhibition of thrombin by antithrombin [83]. 
This requirement is not uniform for inhibition of other proteins by antithrombin, heparin 
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that is as small as a pentasaccharide is able to bind antithrombin and catalyze the 
inhibition of factor Xa [84]. This is the basis for the synthetic heparin-like anticoagulant 
drug Fondaparinux, that specifically stimulates inhibition of FXa by antithrombin. This 
specificity is thought to underlie the reduced bleeding complications that are a feature of 
Fondaparinux compared to unfractionated heparin or low molecular weight heparin [85]. 
  In a similar fashion, the protein also has to have a specific sequence motif to 
facilitate heparin binding. Through analysis of a number of heparin binding proteins, 
initially two heparin binding consensus sequences were proposed: XBBXBX and 
XBBBXXBX, where B is a basic residue and X is a hydrophobic residue. It is suggested 
that if the XBBXBX sequence is in a β-strand conformation, or the XBBBXXBX 
sequence is folded into an α-helix, lysine and arginine residues would be exposed, while 
hydrophobic residues would be pointing into the protein core [86]. However, a third 
heparin binding consensus sequence has been proposed, XBBBXXBBBXXBBX, which 
is found in vWF [87]. Although consensus sequence is a valuable tool in screening for 
potential heparin binding sites, many heparin binding proteins do not contain these 
specific sequences. Folding of the protein may be the determining factor in heparin 
binding, as it can bring distant basic residues into close proximity and thus facilitate 
heparin binding [77]. It was also found that, regardless of the tertiary structure, a distance 
of 20 Å between basic residues was able to facilitate heparin binding [88]. 
Heparin has been used as an anticoagulant therapeutic agent for deep venous 
thrombosis in clinical settings since the 1930s. One of the main uses of heparin is to 
prevent thrombus growth and pulmonary embolism, though accelerated inhibition of the 
proteases involved in the coagulation cascade. Unfractionated heparin is administered 
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intravenously as a treatment for venous thrombosis. However, due to variable individual 
responses to unfractionated heparin, appropriate dosage has been one of the problems 
associated with this therapy [89,90]. Another problem associated with heparin therapy is 
heparin-induced thrombocytopenia (HIT). Several types of HIT have been defined. 
However, only one type is associated with an increased risk of thrombosis. This type of 
HIT is induced by an immune response. Platelet Factor 4 (PF4) is a molecule that gets 
released from platelet granules upon activation of platelets. PF4 is a positively charged 
molecule that binds to the negatively charged heparin molecule. Patients that are 
diagnosed with this type of HIT produce an IgG antibody against the PF4-heparin 
complex. This antibody has the ability to bind to platelets through an Fc receptor and 
induce activation of platelets, followed by activation of coagulation, and thrombus 
formation. This type of HIT is also associated with the decrease of platelets, as antibody-
coated platelets get cleared by phagocytic cells [91]. Therapeutically introduced heparin, 
as well as endogenous heparin gets cleared from the body. It has been previously reported 
that liver sinusoidal endothelial cells of the lymph nodes, liver, and spleen are the 
principal site of clearance of heparin from the vascular and lymphatic circulation [92]. 
These cells express a hyaluronic acid receptor (HARE), also known as Stabilin-2, an 
endocytic receptor that is responsible for binding, internalizing, and degradation of 
heparin [93].   
Interaction of heparin with antithrombin and heparin cofactor II is the basis of its 
anticoagulant activity. However, heparin also binds to TAFI, leading to increased 
activation of TAFI by plasmin, as well as increased stability of TAFIa [43]. Several forms 
of heparin-like glycosaminoglycans tested, such as heparan sulfate, low molecular weight 
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heparin, chondroitin sulfate, keratan sulfate, and dextran sulfate, have a similar effect on 
TAFIa activation by plasmin [43]. Like heparan sulfate, chondroitin sulfate and keratan 
sulfate are expressed by various mammalian cells [94]. Low molecular weight heparin is 
a derivative of the unfractionated heparin [95], while dextran sulfate is synthetic analogue 
of heparin [96]. Chondroitin sulfate contains the same major disaccharide repeat as 
heparin and heparan sulfate, D-glucuronic acid and D-glucosamine, while keratan sulfate 
contains a disaccharide repeat of D-galactose and D glucosamine [94]. Since TAFIa 
attenuates fibrinolysis, heparin may now act as an antifibrinolytic molecule. Little is 
known about this function of heparin, as it was recently discovered. However, this may be 
an important aspect to consider when heparin is administered as an anticoagulant drug.   
 
1.5 Potential TAFI-Heparin Interactions 
Glycosaminoglycans, such as heparin, have been reported to accelerate activation 
of TAFI by plasmin and increase the half-life life of TAFIa [43].  However, the binding 
sites of heparin on TAFI are still unknown. Several reports of the crystal structure of 
TAFI, in the presence of sulfate ions, have shed some light on the potential interaction 
sites of TAFI and glycosaminoglycans (Figure 1-3) [50,51]. Mao and coworkers have 
reported that, based on the sequence analysis, Trp210-Ser221 is a potential binding site. 
This region possesses sequence similarity to that of other glycosaminoglycan binding 
proteins [43]. However, according to the crystal structure of bovine TAFI, in the presence 
of sulfate ions, only one out twenty two sulfate molecules was bound to that region of 
TAFI. The rest of the sulfate molecules were bound to the pro-domain region, the region 
from the instability region to the active site cleft, as well as the instability region. 
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However, it should be noted, that binding of heparin in the segment spanning between the 
instability region and the active site cleft would actually hinder the substrate binding and 
therefore interfere with the carboxypeptidase activity of TAFI. While binding of heparin 
in the pro-domain may be important for various biological activities of TAFI, it would not 
explain the increased stability of TAFIa. Binding of heparin to the instability region of 
TAFI would explain the increased half-life of TAFIa in the presence of heparin [51].  
Since therapeutic manipulation of TAFI function by heparin is a potentially important 
goal, and since clinically used heparins and heparin analogues may be compromised by 
their effect on the balance between coagulation and fibrinolysis through modulation of 
TAFI, we undertook this study to define heparin binding sites on TAFI.
21 
 
 
 
Figure 1-3. Potential glycosaminoglycan binding sites on TAFI. The ribbon 
representation of bovine TAFI (taken from ref. 50) is on the left. Bound sulfates, which 
represent potential glycosaminoglycan binding sites are clustered in three regions: at the 
activation peptide (blue sulfates), at the dynamic region (orange sulfates), and within the 
active site cleft (purple sulfates). Glycosaminoglycan binding to the active site would 
most likely hinder enzymatic activity of TAFIa, therefore it is unlikely to be a site of 
heparin binding. The ribbon representation on the right was prepared from the 
crystallographic data PDB #3D66 (Marx, 2008). A putative glycosaminoglycan-binding 
site spanning Trp210-Met215, contains –XBBXBX- motif where X represents hydrophobic 
residues (green side chains) and B represents basic residues (blue side chains). Also 
shown is the position of Arg92, which is the site of TAFI cleavage by thrombin or 
plasmin. 
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1.6 Overall Hypothesis and Specific Objectives 
The overall goal of this study is to begin to understand the interactions between 
heparin and TAFI, and the resulting biological effects of these interactions in terms of 
plasmin-mediated activation of TAFI and thermal stability of TAFIa. It has been 
previously reported that the presence of heparin increases plasmin-mediated TAFI 
activation and TAFIa stability. However, the interactions that are responsible for these 
effects remain unknown. By mutating basic residues in the potential heparin binding sites, 
we will attempt to determine if these residues participate in heparin binding. Hence these 
TAFI variants will be used to study the overall hypothesis that the residues that 
potentially participate in heparin binding are responsible for either increased TAFI 
activation by plasmin or increased thermal stability of TAFI in the presence of heparin, 
or both. The aim of the current study is to develop TAFI mutants impaired in heparin 
binding, and to determine the effect of this impairment on plasmin-mediated activation of 
TAFI and thermal stability of TAFIa in the presence of heparin.  
The specific objectives of the current study are as follows: 
1. Construction and expression of a series of TAFI variants. 
2. Evaluation of binding of TAFI variants to heparin using an affinity 
chromatography approach. 
3. Characterization of activation kinetics of the TAFI variants by plasmin in the 
presence and absence of heparin. 
4. Characterization of the thermal stability of each TAFI variant in the presence and 
absence of heparin. 
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Chapter 2 
Materials and Methods 
 
Materials          
The synthetic carboxypeptidase substrate anisylazoformyarginine (AAFR) was 
obtained from Bachem Americas Inc (Torrance, CA, US).The plasmin inhibitor D-
valylphenylalanyllysyl chloromethylketone (VFKck), the TAFIa inhibitor DL-2-
mercaptomethyl-3-guanidinoethylthiopropanoic acid (Plummer’s inhibitor) and the 
thrombin inhibitor D-phenylalanylprolylarginyl chloromethylketone (PPAck) were 
purchased from Calbiochem (San Diego, CA, US). Heparin sodium salt from porcine 
intestinal mucosa and heparin-agarose type I saline suspensionwere purchased from 
Sigma-Aldrich (Oakville, ON, CA). QuikChange mutagenesis kit was purchased from 
Stratagene (La Jolla, CA, US). Restriction enzymes were purchased from New England 
Biolabs (Mississauga, ON, CA). Oligonucleotides for mutagenesis were purchased from 
Integrated DNA Technologies, Inc. (Coralville, IA, US). Dulbecco’s modified Eagle’s 
medium/nutrient mixture F-12, Opti-MEM, Trypsin-EDTA, and 
penicillin/streptomyocin/fungizone (PSF) wereobtained from Gibco/Invitrogen 
(Burlington, ON, CA). Newborn calf serum (NCS) was obtained from Sigma-Aldrich 
Canada Ltd (Oakville, ON, CA). Effectene transfection reagent was purchased from 
Qiagen (Toronto, ON, CA). Methotrexate was purchased from Mayne Pharma (Montreal, 
QC, CA). Amicon ultra-4 Centrifugal filter units, MWCO 10kDa were purchased from 
Millipore (Billerica, MA, US). Thrombin, rabbit-lung TM and plasmin were obtained 
from Haematologic Technologies (Essex Junction, VT, US). Polyclonal sheep anti-human 
TAFI antibody was purchased from Affinity Biologicals (Ancaster, ON, CA), polyclonal 
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rabbit anti-sheep antibody was purchased from ThermoFisher Scientific (Ottawa, ON, 
CA). Enhanced chemiluminescent western blotting substrate was purchased from Thermo 
Scientific Pierce Biology Products (Rockford, Illinois, US). Monoclonal anti-TAFI 
antibody MA-T4E3 (purchased from Dr. Ann Gils’ laboratory, Leuven, Belgium) was 
coupled to CNBr -activated Sepharose 4B (GE Healthcare Life Sciences, Mississauga, 
ON, CA) according to the manufacturer’s instructions (2-6 mg antibody/mL resin). 
Western blot imaging was done using Alpha Inotech Fluor Chem Q imager. 
Spectrophotometry experiments were performed using a SpectraMax Plus 384 
spectrophotometer. 
Construction of TAFI Mutants 
Mutagenesis was carried out using the Quik-Change mutagenesis kit (Stratagene) 
as per the manufacturer’s standard protocol. In all cases, the template for the mutagenesis 
was TAFI-pNUT, which contains a cDNA encoding human TAFI that has threonine at 
positions 147 and 325. TAFI variants with threonine at 325 have a half-life of about 8 
minutes whereas isoleucine at this position can increase half-life to about 15 minutes [55]. 
The presence of the mutations was verified by DNA sequence analysis. Creation of the 
variant R320A/K324A was carried out by Ashley Kellam prior to my arrival in the 
laboratory. Creation of R15A was carried out by Tanya Marar. 
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Table 2-1 Primer design used for construction of the variants used in this study. 
Sense strand of each primer is shown. Location of the primer binding region is indicated 
by the number above the primer sequence. Nucleotides that are mismatched between the 
primer and template are underlined. 
Variant Primers 
K327A    1046 
5’TTCGTGCTATTGAGAAAACTAGTGCAAATACCAGGTATACACATGGCC3’ 
 
K327A/R330A    1046 
5’TTCGTGCTATTGAGAAACTAGTGCAAATACCGCGTATACACATGGCCATGGCTCAG3’ 
 
H308F     991 
5’ ACACGAAGTAAAAGCAAAGACTTTGAGGAACTGTCTCTAGTAGC3’ 
 
K306A     986 
5’ CCTATACACGAAGTAAAAGCGCAGACCATGAGGAACTGTCTC 3’ 
 
K212A     704 
5’GTTATGACTACTCATGGAAAGCGAATCGAATGTGGAGAAAG3’ 
 
K211Q/K212Q     697 
5’ GTGGACGGTTATGACTACTCATGGCAACAGAATCGAATGTGGAGAAAGAACCG 3’ 
 
R320A/K324A     1020 
5’ACTGTCTCTAGTAGCCAGTGAAGCAGTTGCTGCTATTGAGGCAACTAGTAAAAATACC 3’ 
 
R15A      110 
5'-TAGCTGCTCTTCCTAGAACCTCTGCGCAAGTTCAAGTTCT-3' 
 
K59A     240 
5’AAATGCATCTGATGTCGACAATGTGGCAGCCCATTTAAATGTGAGC3’ 
 
S316A     1017 
5'-GGAACTGTCTCTAGTAGCCGCTGAAGCAGTTCGTGCTATT-3' 
 
S249A/S251A     218 
5'-GTGAGGAAGGTGCATCCGCTTCCGCATGCTCGGAAACCTAC-3' 
 
26 
 
 
Expression and Purification of Recombinant TAFI Variants 
BHK cells were cultured in complete medium (DMEM/F12 containing 5% (v/v) 
NCS and 1% (v/v) PSF) in a humidified incubator at 37°C in a 95% air/5% CO 2 
atmosphere. Expression plasmids encoding the respective TAFI variants were transfected 
into cells using Effectene reagent, employing  2 μg plasmid DNA and 60 μL of 
transfection reagent per 100 mm plate of cells. After 24 h incubation with the transfection 
mixture, the cells were then cultured in complete medium containing 400 μM 
methotrexate for approximately 2 weeks, with the medium changed every other day, for 
the selection of stable cell lines expressing the respective recombinant TAFI variants. For 
recombinant TAFI production, stably expressing lines were cultured in triple flasks (500 
cm
2
, Nunc, Roskilde, Denmark) in Opti-MEM containing 1% (v/v) PSF and 40 μM 
ZnCl
2
. Medium was collected every 72 h and replaced with fresh medium. Harvested 
medium was centrifuged at 3000 × g for 5 minutes to pellet cell debris, supplemented 
with Tris-HCl, pH 8.0 (to 5 mM), reduced glutathione (to 0.5 mM) and 
phenylmethanesulphonylfluoride (PMSF) to (2 μM) and stored at -20°C. To purify the 
TAFI variants, conditioned medium was passed through a 0.22 µm filter and then over a 1 
mL MA-T4E3-Sepharose column at 4°C. The column was washed with a 100 ml of 
HBST (20 mM HEPES pH 7.4, 150 mM NaCl, 0.01% (v/v) Tween 80). TAFI that was 
bound to the column was eluted with 1-mL aliquots of 0.2 M glycine pH 3. Fractions 
were collected into 0.5-mL aliquots of 1M Tris-HCl, pH 8. Protein-containing fractions 
were pooled, and then were concentrated, and exchanged into HBST using Amicon ultra-
4 Centrifugal filter units, MWCO 10kDa. Purified and concentrated TAFI was quantified 
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by measurement of absorbance at 280 nm (ε1%, 280 = 26.4, Mr= 60,000), aliquoted and 
stored at -70°C. 
 
Binding of TAFI to Heparin 
A 1-ml heparin-agarose column was prepared by equilibrating the column with 10 
column volumes of HBS. TAFI (0.00025 mg) was applied to the column. TAFI was then 
eluted with 12 fractions (200 µL each) of HBS, followed by 12 fractions of HBS 
containing heparin (0.177 U/µL). TAFI content in each fraction was determined through 
SDS-PAGE and western blotting.  
 
 Thermal Stability of TAFI in the Presence and Absence of Heparin. 
Purified recombinant TAFI variants (1 μM) were activated by incubation with 
thrombin (25 nM). TM (100 nM), CaCl2 (5mM) in HBST at 24°C for 15 min. The 
thrombin was then quenched by the addition of PPAck (to 1 μM). Activated TAFI was 
divided into aliquots corresponding to various time points and incubated at 37°C in the 
presence or absence of heparin (0.6 U/µL). At each time point, aliquots were placed on 
ice. Following the final time point, 15 μl of each aliquot was  mixed with 35 μl HBST and 
50 μl AAFR (120 μM final concentration) in a microtitre plate, and the initial rates of 
substrate hydrolysis were measured at 350 nm. The carboxypeptidase B function of 
TAFIa hydrolyzes AAFR according to the following reaction: 
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(Scheme 1) 
Before the anisylazoformyl moiety is removed, AAFR strongly absorbs at 350 nm. Upon 
the removal of this moiety, the resultant products do not absorb at this wavelength. 
 The hydrolysis rate was directly related to the activity of TAFIa and related to the 
initial TAFIa activity by dividing the initial hydrolysis rate by the hydrolysis rate at each 
respective time point. This relationship was plotted as a function of time. Non-linear 
regression to the equation for first-order exponential decay (SigmaPlot 11.0, SPSS Inc., 
Chicago, IL) was used to fit the data in order to obtain rate constants from which the half-
lives of each variant could be calculated: 
[TAFIa]=[TAFIa]0*e
-k*t 
              (Equation 1) 
Where [TAFIa]0 is the initial TAFIa concentration,[TAFIa] is the residual concentration at 
each time point, and  k, is the first order decay constant obtained from the non-linear 
regression in SigmaPlot. 
Half-life is defined as the time when [TAFIa]=0.5*[TAFIa]0, 
0.5*[TAFI]0=[ TAFIa]0*e
-k*t 
         
0.5=e
-k*t 
         
t=-ln(0.5)/k          (Equation 2) 
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The half-life of each variant is thus obtained by substituting the decay constant k into the 
equation (2). 
 
Kinetics of Activation of TAFI Mutants by Plasmin in the Presence or Absence of 
Heparin. 
 For activation by plasmin, a range of concentrations of the TAFI variants (0.01-
0.1 µM) was incubated with 25nM plasmin, and 5 µM Plummer’s inhibitor in the 
presence or absence of heparin  0.2 U/µL for 12 min at 24ºC . Reactions were stopped by 
the addition of VFKck (1µM final concentration). SDS-PAGE sample buffer (0.2 M Tris-
HCl, 8% SDS, 40% Glycerol, 0.08% bromophenol blue) was immediately added to the 
samples. Samples were analyzed by SDS-PAGE and western blotting with the goat anti- 
human TAFI polyclonal antibody. A TAFIa standard curve was prepared along with each 
kinetic experiment. A TAFIa standard solution was made by activating 1 µM TAFI for 10 
min at 24 ˚C in the presence of HBST, 25 nm thrombin, 100 nm thrombomodulin, 5 mM 
CaCl2 to achieve complete activation of TAFI to TAFIa. TAFIa was then serially diluted 
to concentrations of 0.0053-0.04 µM and then subjected to SDS-PAGE and western 
blotting like the kinetic samples. For a given experiment, all blots containing standards 
and samples were processed simultaneously for visualization of immunoreactive bands or 
order for the standard curve to be applicable to the samples. The densities of the 35 kDa 
TAFIa and 25 kDa TAFIai bands were quantified using AlphaView SA software. A 
standard curve was constructed by plotting the density of each standard TAFIa sample 
against its concentration. The TAFIa concentrations formed in each kinetic run were thus 
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obtained by interpolating the densities on the standard curve. The concentration of TAFIa 
formed was then converted to the rate of TAFIa formation (moles of TAFIa formed per 
second per mole of plasmin). The data were fit to the Michaelis-Menten equation 
(Sigmaplot 11.0, SPSS Inc., Chicago, IL). 
V=kcat[E]T[S]/(KM+[S])         (Equation 3) 
Although the data were fit to the Michaelis-Menten equation, the kcat and Km values that 
will be reported are apparent values, and referred to as kcat(app) Km(app) respectively. Since 
the substrate concentrations and the enzyme concentrations are comparable, the 
Michaelis-Menten assumption of a steady state [ES] and saturations of E with S do not 
hold. In an attempt to account for this, the data were fit to the quadratic form of the 
Michaelis-Menten equation (Equation 4), but the data sets did not give a reasonable fit to 
this equation. Thus, the Michaelis-Menten equation was employed to give apparent 
constants that can at least be operationally compared to each other. 
V= kcat (0.5* (Km +[E]T+[S]T-((Km+[S]T)
2
-4*([E]T[S]T))
1/2
))   (Equation 4) 
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Chapter 3 
Results          
 
3.1 Construction and Expression of TAFI Variants 
 In order to assess potential heparin binding sites of TAFI, a number of TAFI 
variants were designed that contained mutations of potential residues involved in heparin 
binding. Based on the crystal structure of bovine TAFI in the presence of sulfate ions 
[50],where the negatively charged sulfate ions, in complex with TAFI, were suggested to 
represent potential heparin binding sites, Anand and coworkers identified four potential 
regions of heparin binding. Of these, we selected two of the regions for our mutagenesis 
(Fig 3-1; Table 3-1).  The first region identified by Anand and coworkers was Trp210-
Ser221.  It also was previously reported that this region shows sequence similarity with 
other glycosaminoglycan binding proteins [43,51].  In the crystal structure of bovine 
TAFI, one out of 22 sulfate molecules was bound to this region at Lysine 212 [51]. The 
second region that had a set of bound sulfates is the region running from the instability 
region to the active site cleft. However, it was suggested that heparin binding in this 
region would actually hinder binding of TAFI substrates, and thus interfere with 
carboxypeptidase activity of TAFI. Therefore, we did not pursue mutagenesis in this 
region. The third region of interest was Ser305-His335, which is the instability region of 
TAFI. Binding of heparin to this region would explain the increased half-life of TAFI and 
therefore a number of mutations were made in this region. Five sulfates were also bound 
to the pro-domain. However, binding of heparin to this region would not explain the 
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increased stability of TAFI [51]. Regions Trp210-Ser211 and Ser305-His335 were 
therefore the focus of this study. Table 3-1 summarizes the variants that were pursued. 
Figure 3-1 shows an alignment of bovine and human TAFI.  
 
 
Figure 3-1. Alignment of bovine and human TAFI amino acid sequences. Two 
regions of interest, that contained bound sulfates, are circled, with arrows indicating the 
residues that were mutated in this study.    
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Table 3-1. Recombinant TAFI variants used in this study.  The majority of the 
mutations were made on based on the bound sulfates, with the exception of 
K211Q/K212Q, and R320A/K324A. 
Variant Region Rationale 
K212A Sequence similarity with GAG 
binding proteins 
Bound sulfate 
K211Q/K212Q Sequence similarity with 
heparin GAG binding proteins 
Sulfate may be bound to the 
neighbouring lysine in human 
TAFI 
K327A Instability region Bound sulfate 
K327A/R330A Instability region Bound sulfate 
H308F Instability region Bound sulfate 
K306A Instability region Bound sulfate 
R320A/K324A Instability region Charged, exposed residues. In 
close proximity to sulfate-
binding residues that are not 
conserved between bovine and 
human TAFI. 
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Variant K212A was pursued because a sulfate molecule was bound to lysine 212 in the 
bovine TAFI crystal structure. Since the three-dimensional shape of the bovine TAFI 
molecule slightly differs from that of the human TAFI, it is possible that that the sulfate 
molecule could bind to the neighbouring lysine residue, 211. Therefore, both lysines, 211 
and 212, were mutated.  Originally, the double mutation of the two lysine residues (211, 
212) was intended to be to two alanine residues. However these mutations did not result 
in detectable secreted protein. Therefore both lysine residues were mutated to glutamine 
residues, as this polar residue might be better accommodated on the surface of the protein. 
Variants K327A, K327A/R330A, H308F, K306A were pursued due to the binding of the 
sulfate ions to these residues. The majority of these variants contained a mutation to an 
alanine, with the exception of the H308F, where the charged histidine residue was 
mutated to phenylalanine to preserve the presence of an aromatic ring. A number of 
sulfate ions were bound to residues, in the instability region, that are not conserved 
between human and bovine TAFI, therefore neighbouring exposed charged residues, such 
as arginine 320 and lysine 324 were mutated to an alanine.
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3.2 Binding of TAFI variants to heparin-agarose  
 Both bovine and human TAFI  have been shown to bind heparin, through the use 
of heparin-sepharose, as the majority of the protein was eluted with high salt 
concentrations [52]. We employed a similar method. However, after the protein was 
applied to the column, and following the HBS wash, bound proteins were eluted with 
HBS containing heparin, to more conclusively demonstrate spesific binding of TAFI to 
heparin. Figure 3-2 summarizes the elution profile of wild-type TAFI and other TAFI 
variants. As predicted, wild-type TAFI remained bound to heparin throughout a series of 
wash fractions (2.4X column volumes), and was eluted with the addition of heparin.To 
demonstrate the specificity of TAFI binding to the immobilized heparin, rather than the 
agarose itself, a similar binding experiment was conducted using a column containing 
unconjugated agarose beads. TAFI eluted in the wash fractions and heparin did not result 
in any further elution of TAFI, suggesting that none of the applied TAFI bound non-
specifically to agarose. Some of the variants exhibit an elution profile similar to wild-
type. However, K211A, K211Q/K212Q, K327A, as well as K327A/R330A exhibit a two 
peak elution pattern, indicating either a reduced affinity for heparin or that there may be 
both a binding and a non-binding fractions. Variant R320A/K324A appers to have lower 
affinity for heparin-agarose, as it is almost entirely eluted in the HBS was
36 
 
 
 
F
ig
u
re
 3
-2
 B
in
d
in
g
 o
f 
T
A
F
I 
v
a
ri
a
n
ts
 t
o
 h
ep
a
ri
n
-a
g
a
ro
se
. 
T
A
F
I 
w
as
 a
p
p
li
ed
 t
o
 a
 h
ep
ar
in
-
ag
ar
o
se
 c
o
lu
m
n
, 
fo
ll
o
w
ed
 b
y
 a
n
 H
B
S
 w
as
h
, 
an
d
 h
ep
ar
in
 w
as
h
. 
T
h
e 
el
u
ti
o
n
 p
ro
fi
le
 o
f 
ea
ch
 
v
ar
ia
n
t 
is
 r
ep
re
se
n
ta
ti
v
e 
o
f 
it
s 
af
fi
n
it
y
 f
o
r 
h
ep
ar
in
-a
g
ar
o
se
. 
W
il
d
-t
y
p
e 
T
A
F
I 
w
as
 a
ls
o
 a
p
p
li
ed
 t
o
 
an
 a
g
ar
o
se
 c
o
lu
m
n
 t
o
 a
cc
o
u
n
t 
fo
r 
h
ep
ar
in
-i
n
d
ep
en
d
an
t 
b
in
d
in
g
 t
o
 a
g
ar
o
se
. 
T
h
e 
d
et
ec
ti
o
n
 o
f 
T
A
F
I 
co
n
te
n
t 
in
 e
ac
h
 f
ra
ct
io
n
 w
as
 d
o
n
e 
th
ro
u
g
h
 w
es
te
rn
 b
lo
tt
in
g
 
 
 
 
37 
 
 
 
 
3.3 Kinetics of activation of TAFI variants by plasmin in absence and presence of 
heparin 
 The activation of TAFI by plasmin is accelerated in the presence of heparin, an 
effect expressed by a 5.9-fold increase in kcat and a 2.7-fold decrease in Km [43].The 
contribution that several potential heparin-binding residues have on the acceleration of 
TAFI activation by plasmin in the presence heparin was analyzed by western blot 
analysis. Table 3-2 and Figure 3-3 summarize the kinetic parameters of activation of 
TAFI variants by plasmin in absence and presence of heparin. To varying degrees, 
activation of all of the variants by plasmin is accelerated when heparin is present, 
indicating that none of the mutated residues completely abolish the stimulating effect 
heparin has on TAFI activation by plasmin. Variants K212A, K327A/R330A, and H308F 
exhibit the greatest enhancement of catalytic efficiency in the presence of heparin, and in 
each case this reflects a lower catalytic efficiency in the absence of heparin. The degree of 
rate enhancement by heparin is considerably lower for variants K211Q/K212Q and 
R320A/K324A, with the fold difference in the catalytic efficiency being 1.3- and 1.2-fold 
respectively, compared to wild-type, which is 1.5-fold. Compared to wild-type TAFI and 
most of the other variants, a substantial increase in Km was observed for each of these 
variants both in the absence and presence of heparin, which indicates a reduced affinity of 
plasmin for these variants. Although variant K306A does not show a difference with 
wild-type with respect to fold increase in catalytic efficiency in the presence of heparin, 
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inspection of Figure 3-3f does show a clear decrease in the magnitude of the effect of 
heparin, compared to wild-type TAFI and most other variants. We suspect that the 
Km(app) of this variant in the absence of heparin has been over-estimated: at these low 
rates, we are approaching the limit of sensitivity of the western blot assay.  
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Table 3-2. Activation of TAFI variants by plasmin in the absence and presence of 
heparin. kcat (app) and Km (app) values were determined from the data in Figure 3-3. The 
standard error of kcat (app) and KM (app) were estimated by the regression algorithm in 
SigmaPlot 11. 
Variant  
 
kcat(app) (s
-1) Km (app) (µM) kcat(app)/Km(app)(µM
-1. s-1) kcat(app)/
Km(app) 
fold 
increase 
n 
 +heparin -heparin +heparin -heparin +heparin -heparin 
TAFIwt 0.00190±0.00004 
 
0.00070±0.00007 
 
0.036±0.002 
 
0.021±0.0
05 
 
0.051 
 
0.033 1.5 3 
K327A 0.00220±0.00050 0.00060±0.00006 0.040±0.018 0.018±0.0
04 
0.053 
 
0.032 
 
1.6 3 
K327A/ 
R330A 
0.00190±0.00030 0.00100±0.00004 0.049±0.013 
 
0.063±0.0
04 
0.039 0.016 2.4 3 
H308F 0.00190±0.00010 
 
0.00100±0.00006 0.032±0.005 0.039±0.0
10 
 
0.059 0.025 2.3 3 
K212A 
 
0.00280±0.00060 
 
0.00110±0.0004 
 
0.067±0.003 
 
0.071±0.0
09 
0.041 
 
0.015 
 
2.7 3 
K211Q/
K212Q 
0.00150±0.00030 
 
0.00090±0.00020 
 
0.096±0.031 
 
0.076±0.0
29 
0.014 0.011 1.3 3 
R320A/
K324A 
0.00720±0.00140 0.00330±0.00010 0.309±0.072 0.168±0.0
68 
0.023 0.019 1.2 2 
K306A 0.00230±0.00040 0.00190±0.00010 0.122±0.031 0.157±0.0
17 
0.019 0.012 1.6 2 
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Figure 3-3 Activation of TAFI variants by plasmin in the presence or absence of 
heparin. Various concentrations of wild-type TAFI (a), K327A (b), K327A/R330A (c), 
H308F (d), K212A (e), K211Q/K212Q (f), R320A/K324A (g), K306A (h) were 
incubated with 25 nM plasmin, in the presence (circle) or absence (cross) of 0.02 U/µL 
heparin for 12 min at room temperature. The rates of activation were calculated and the 
data were fit to the Michaelis-Menten equation. Each point represents the mean of at least 
two experiments, with the error bars representing the standard error of the mean (for n≥3) 
or the range of the data (for n=2). The lines are regression lines calculated from the fit 
parameters. 
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3.4 Thermal Stability of TAFI variants in the Presence and Absence of Heparin 
 Activated TAFI is a highly unstable enzyme. Depending on the isoform, the half-
life of TAFI is 8-15 minutes [55]. It has been previously shown that thermal instability of 
TAFI is responsible for the inactivation of the enzyme and influences its antifibrinolytic 
potential [48]. Heparin has been shown to increase the half-life of TAFIa [43]. Although 
the study of the effect of heparin on the stability of TAFIa was previously done at 25˚C, 
increasing the half-life from 74 min to 170 min [43], we hypothesized that heparin would 
have a similar stabilizing effect at 37˚C.  It was determined that heparin does stabilize 
TAFIa at body temperature, increasing the half-life from for the wild-type enzyme from   
6.4 minutes to  10.8 minutes (Table 3-4). The specific enzymatic activity of all of the 
variants ranged between 68 % of wild-type (K211Q/K212Q) and 124% of wild-type  
(R320A/R330A), trends that were not markedly altered by the presence of heparin (data 
not shown).The contribution of the various residues to the TAFIa stabilizing effect of 
heparin was determined. Table 3-3 and Figure 3-4 summarise the half-lives of wild-type 
TAFIa compared to the TAFIa variants. Several variants were less stable than wild-type 
TAFI in the absence and presence of heparin, while the R320A/K324A variant was more 
stable than wild-type TAFIa in the absence of heparin. Some of the variants exhibited a 
considerably reduced stabilizing effect of heparin, when compared to the wild-type 
enzyme: specifically K327A, K327A/R330A, K212A, and R320A/K324A, which 
corresponds to the lowest fold increase in the half-life in the presence and absence of 
heparin in these variants.
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Table 3-3. The intrinsic stability of TAFIa variants in the absence and presence of 
heparin at 37˚C.  Decay constants estimated by the regression of the data in Figure 3-4 
were used to calculate the half-lives of the TAFIa mutant in the absence and presence of 
heparin. The data represent the mean of at least 2 experiments. With error representing 
the standard error of the mean (for n≥3) or the range of the data for (n=2). Half-life fold 
increase is a ratio between the half-life of TAFI in the presence and absence of heparin.  
Variant  Half-life Half-life 
fold 
increase 
# of 
replicates +heparin(min) -
heparin(min) 
WT 10.80 ±0.11 6.41±0.53 
 
1.7 3 
K327A 5.87±0.14 4.73±0.42 
 
1.3 3 
K327A/R330A 5.58±0.83 
 
4.29±0.26 1.3 3 
H308F 11.80±0.61 
 
6.64±1.52 
 
1.7 2 
K212A 6.81±0.44 
 
5.08±0.49 
 
1.3 4 
K211Q/K212Q 8.07 ±1.16 
 
5.11±1.10 
 
1.6 3 
K306A 8.19±2.3 
 
4.6±0.59 1.8 4 
R320A/K324A 9.89±0.60 
 
8.51±0.97 
 
1.2 3 
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Figure 3-4 The intrinsic stability of TAFIa variants in the absence and presence of 
heparin at 37˚C. WT(a), K327A(b), K327A/R330A(c), H308F(d), K212A(e), 
K211Q/K212Q(f), R320A/K324A(g), K306A(h) were activated in the presence of 
thrombin-TM, and incubated at 37˚C in the presence (circle) or absence (cross) of 
heparin. TAFIa activity was measured at different time points. The data were fit to the 
equation describing first-order exponential decay in order to determine the half-lives of 
TAFIa. Each point represents the mean of at least two experiments with the error bars 
representing the standard error of the mean (for n≥3) or the range of the data for (n=2). 
The lines are regression lines calculated from the fit parameters. 
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Chapter 4 
Discussion and Conclusion           
                            
4.1 Role of Glycosaminoglycans in the TAFI Pathway 
TAFI pathway has been shown to play a significant role in fibrinolysis by 
removing carboxyl-terminal lysines from partially degraded fibrin thus reducing the 
ability of this material to promote the activation of plasminogen and the conversion of 
Glu-plasminogen to Lys-plasminogen, as well as to protect plasmin from consumption by 
antiplasmin [32,66]. To elicit these effects, TAFI zymogen has to be activated by 
thrombin, thrombin/thrombomodulin complex, or plasmin [34,41]. Even though the TAFI 
pathway has been studied extensively, the contribution of these activators on the localized 
activation of TAFI remains unknown. There is a possibility that none of these activators 
are the exclusive, physiologically relevant, activator of TAFI. Even though the catalytic 
efficiency of thrombin-thrombomodulin activation of TAFI is much greater than that for 
thrombin alone or plasmin [41], the characteristics of the site where the activation takes 
place may be the determining factor of what is the physiologically-relevant activator of 
TAFI at that site. High concentrations of glycosaminoglycans can be found at a site of a 
vascular injury, due to the exposure of the extracellular matrix components. Due to an 
increase in catalytic efficiency of plasmin-mediated activation of TAFI in the presence of 
glycosaminoglycans, it is fair to hypothesize that plasmin is an important activator at a 
site where there is a high concentration of glycosaminoglycans [43]. The majority of the 
endothelial cell cofactor thrombomodulin, however, would be absent at the site of a 
vascular injury, further emphasizing the importance of plasmin-mediated mechanism of 
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TAFI activation [43]. On the other hand, in the situation of an intact endothelial cell 
surface, thrombin/thrombomodulin may be main activator of TAFI [44]. 
 Due to the function of TAFI in regulation of the balance between the coagulation 
and the fibrinolysis, understanding the TAFI pathway would aid in the development of 
either thrombosis or bleeding disorder therapeutics. Current therapy for thrombotic 
disorders heavily relies on the use of heparin, and other heparin-related drugs [89,90]. 
However, heparin therapy has been complicated with the determination of appropriate 
dosage, as well as heparin-induced thrombocytopenia (HIT), resulting in increased 
thrombosis [90,91]. Another potential problem that could arise from heparin therapy is 
increased plasmin-mediated activation of TAFI, as well as increased stability of TAFIa 
[43], which would result in decrease in fibrinolysis and therefore antagonize the 
anticoagulant properties of heparin.   
 The focus of the present study was to develop TAFI variants that are resistant to 
heparin binding and could be used to explore contribution of heparin on activation and 
stability of TAFI in vitro, and eventually in vivo. The number and location of sites on 
TAFI that bind heparin are completely unknown, as is the relationship between these sites 
and the observed effects of heparin on TAFI activation and TAFIa stability. Guided by X-
ray crystallographic data on the structure of TAFI, in the presence of sulfate ions, as well 
as by similarity of certain sequences in TAFI to heparin-binding proteins, we have 
mutated selected residues in the Trp210-Ser221, and Ser305-His335 regions. However, it 
should be noted that the binding of individual sulfates may not necessarily represent bona 
fide heparin-protein interactions, as heparin itself is a polymer of sulfated glycosidic 
units. Therefore it is possible that some of the residues that were associated with a sulfate 
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ion, are not physiologically relevant as heparin binding sites. This might explain why 
mutation of some of the sulfate-bound residues had no effect on heparin binding. 
Molecular docking of a single heparin molecule to TAFI may be a better model for TAFI 
interaction with heparin. Nonetheless we anticipated this model would be indicative of 
some of the heparin binding sites and would lead us to variants resistant to heparin 
binding and thus resistant to enhanced activation by plasmin and to increased thermal 
stability of TAFIa due to heparin. As elaborated below, the results reveal a rather 
complex scenario where no one site definitively eliminated both heparin binding as well 
as the effects of heparin on TAFI activation and/or TAFIa stability. Several of the 
variants displayed impaired heparin binding, as evidenced by a two-peak elution pattern 
where some of the TAFI eluted in the wash fractions of the heparin-agarose column with 
the remainder being specifically eluted by heparin. Some of these variants showed 
reduced plasmin activation acceleration by heparin, while others did not. Likewise, some 
of these variants impaired in heparin binding showed decreased stabilization by heparin 
but others did not.  One variant, R320A/K324A, did exhibit a drastically reduced affinity 
for heparin, with almost all of the protein eluting in the wash fractions. This variant was 
impaired in both acceleration of activation as well as in enzyme stabilization by heparin, 
yet some residual effects of heparin remained. Altogether, these findings shed new light 
on the nature of the TAFI-heparin interaction, and will aid us in future understanding of 
significance of TAFI binding to heparin and other glycosaminoglycans, and the effect of 
the binding on the activation and stability of the enzyme. This knowledge will lead to 
further understanding of modulation of the TAFI pathway via heparin and other 
glycosaminoglycans. 
 
 
52 
 
4.2 Binding of TAFI variants to heparin-agarose. 
 To estimate the contribution of various residues on the binding of TAFI to 
heparin, we employed a heparin-agarose column. We hypothesized that if the mutated 
residue is critical to heparin binding of TAFI, the protein will be eluted from the column 
more readily than the wild-type protein. In fact, wild-type TAFI remained bound to the 
column until the addition of heparin, while one variant, R320A/K324A, was almost 
entirely eluted from the column in the wash fractions with very little remaining for elution 
by heparin. On the other hand, several of variants, namely K211A, K211Q/K212Q, 
K327A, and K327A/R330A, exhibited a two peak elution profile with differing 
characteristic amounts of TAFI eluted in the wash fractions. Each of these mutants 
displayed a relatively consistent elution pattern, when compared between repeated 
experiments. The reason for the two peak elution pattern is unknown. However, it can be 
hypothesized that it results from either a reduced affinity of the variant for the column 
such that a fraction remains unbound under these conditions, or the presence of two 
fractions of TAFI with different affinities for the heparin-agarose.  
 The source of these two fractions may be the existence of two difference different 
glycoforms of TAFI. A previous report on recombinant antithrombin showed that there 
are two major glycoforms of antithrombin present due to both differential usage of the 
one of the glycosylation sites, as well heterogeneous glycosylation at the remaining 
sites.Those glycoforms varied in the affinity to the heparin-agarose up to 10-fold [97]. 
TAFI contains four sites of N-linked glycosylation, all of which are in the activation 
domain of TAFI and all of which appear to be used in all molecules of both recombinant 
and plasma-derived TAFI [39]. One group reported that there is an additional N-linked 
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glycosylation site, not utilized in all molecules of TAFI, in the catalytic domain of 
TAFI[38]. However, subsequent crystallographic data [40] comprehensively debunked 
this notion as the Asn219 residue implicated is buried within the core of the catalytic 
domain. It has been shown that there is microheterogeneity in three of the N-linked 
glycans while the fourth is homogeneous [38]. Mutation of each of four glycosylation 
sites on TAFI could potentially determine which of the sites might contribute to potential 
micoheterogeneity affecting heparin binding. Alternatively, mass spectrometric analysis 
of the glycans present in the binding and non-binding TAFI fractions could be performed. 
However, it is difficult at this time to rationalize how mutations in the catalytic domain of 
TAFI could influence the extent of microheterogeneity in the N-linked glycans on the 
activation peptide.  
 We did rule out the third possibility for the presence of two binding fractions: that 
the TAFI-binding capacity of the heparin column was saturated by the amount of TAFI 
applied. Two factors suggest against this possibility. First, several of the variants 
including wild-type TAFI bound to the column, and eluted in a single peak, despite all 
variants being applied in the same amounts to same-sized columns. In addition, during the 
optimization of this experiment, even after lowering the amount of applied TAFI by 
nearly 10-fold, we still observed a two peak elution pattern for some of the variants. To 
further establish that the column is not saturated, the amount of TAFI for variants in 
question was lower by 1.5-fold. However, a similar elution pattern was observed (data not 
shown).  
 The next step in comparing the contribution of various residues on binding of 
TAFI to heparin, would be to perform equilibrium binding experiments to determine the 
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dissociation constant (Kd) of the TAFI variants for binding to heparin. We did investigate 
two different approaches to measuring this value. First, we purchased fluorescently-
labeled heparin and titrated this material with TAFI while measuring the fluorescence 
intensity. If binding to TAFI increased or decreased the quantum yield of the heparin-
bound flourophore, the data could have been used to arrive at a Kd. However, no change 
in fluorescence was observed, suggesting that binding of TAFI did not alter the chemical 
environment of the fluorophore. Similar solution-phase experiments can be envisaged, 
such as using fluorescently-labeling TAFI, measuring changes in fluorescence anisotropy, 
or measuring changes in light-scattering intensity. 
 We also attempted a equilibrium binding analysis using a ligand binding assay 
where heparin-agarose was incubated with various concentrations of TAFI; following 
pelleting of the heparin-agarose by brief centrifugation, the TAFI concentration in the 
supernatant (representing the unbound fraction) was measured using either western 
blotting or enzyme-linked immunosorbent assay (ELISA). The results we observed are 
summarized in the Appendix. However, clear evidence for specific, saturable binding 
could not be obtained within the limited timeframe available; clearly, more optimization 
for the experiment is needed.  
 Overall, it can be concluded that variant R320A/R324A exhibited the lowest 
affinity for heparin agarose, as it was almost entirely eluted in a single peak, during the 
wash. Variants K211A, K211Q/K212Q, K327A, and K327A/R330A eluted in a two-peak 
manner. 
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4.3 Kinetics of activation of TAFI variants by plasmin in absence and presence of 
heparin 
 Plasmin is an active form of the proenzyme plasminogen,that results from the 
cleavage of plasminogen Arg561-Val562 peptide bond [68]. It was previously reported 
that plasmin-mediated activation of TAFI is accelerated in the presence of heparin [43]. 
Mao and coworkers activated TAFI with either thrombin or plasmin in the presence and 
absence of heparin. They found that heparin had no effect on activation of TAFI by 
thrombin, while enhancing catalytic efficiency of plasmin-mediated activation of TAFI 
16 fold [43]. In the current study we examined the contribution of various residues on 
plasmin-mediated activation in the presence or absence of heparin. We found that all of 
the TAFI variants exhibited accelerated activation by plasmin in the presence of heparin, 
to a certain degree. While Mao and coworkers observed a 16-fold increase in catalytic 
efficiency in the presence of heparin in the case of the wild-type enzyme, we determined 
the catalytic fold increase to be 1.5. However we observed kcat(app) values in the presence 
and absence of heparin to be 0.00190 s
-1
 and 0.00070 s
-1
 respectively. These values are 
similar to those reported by Mao and coworkers, 0.0026 s
-1
 and 0.00044 s
-1
 in the 
presence and absence of heparin respectively. In the current study, we found that 
Km(app)values were similar, within error, in the presence and absence and heparin. Mao 
and coworkers found a decrease in Km in the presence of heparin, while we tended to 
observe an increase, accounting for the differences in fold increase in catalytic efficiency 
between the two studies. It is possible, from inspection of our data, especially in the 
absence of heparin, that we were approaching the limits of sensitivity of our western blot 
assay and thus may have overestimated the extent of TAFI activation at low 
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concentrations of substrate, thus artificially decreasing Km(app). Indeed, our Km in the 
absence of heparin for wild-type TAFI was 0.021 µM, versus 0.055 µM reported by Mao 
and coworkers. To more accurately estimate Km, we would have had to use even lower 
concentrations of TAFI which would have further compromised the accuracy of our 
assay. Moreover, we were not able to fit our data to the quadratic form of the Michaelis-
Menten equation, which may have altered our estimates of kcat and Km. Nonetheless, our 
kinetic data at higher TAFI concentrations clearly show a marked effect of heparin on the 
rate of TAFI activation. By examining the kinetic data (Fig 3-3) and the obtained kinetic 
parameters (Table 3-2) for plasmin-mediated activation of different variants, it is evident 
that the lowest degree of rate enhancement is exhibited by variants K211Q/K212Q and 
R320A/K324A. However, this is not well represented in a reduced fold kcat/Km difference 
likely due, as argued above, that the true extent of enhancement of catalytic efficiency of 
wild-type TAFI is underestimated. Nonetheless, variants K211Q/K212Q and 
R320A/K324A exhibit the lowest fold difference in kcat/Km between plasmin-mediated 
activation in the presence or absence of heparin. Although the fold difference in kcat/Km in 
the presence and absence of heparin in the case of mutant K306A is similar to that of 
wild-type, through the analysis of the Figure 3-3f, it appears that heparin has a reduced 
effect on plasmin-mediated activation of this variant. This could be due to the 
aforementioned inaccuracy of Km(app) estimation. It is evident that the rate of plasmin-
mediated activation of variants K211Q/K212Q and R320A/K324A, as well as K306A, is 
substantially lower, an effect attributable mostly to higher Km(app) values for these 
variants. These data suggest that these residues play a role in interacting with plasmin.  
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 Plasmin consists of two disulfide-bonded chains. The light chain consists of a 
trypsin-like protease domain; plasmin displays comparatively broad substrate specificity 
and the protease domain itself makes limited contacts with the substrate outside of the 
residues surrounding the scissile bond. The heavy chain, however, consists of five kringle 
domains. Kringle domains are tri-looped structures, containing six invariant disulfide 
bonds,that are thought to mediate protein-protein interactions. Indeed, kringles 1 and 4 of 
plasmin contain high affinity lysine-binding sites that participate in maintaining the 
closed conformation of native plasminogen and in binding interactions with basic 
residues on substrates such as fibrin and antiplasmin [69,99]. Although there are few 
reports characterizing plasmin-TAFI interactions, several residues have been identified to 
be important in the formation of the TAFI-plasmin complex, and therefore activation of 
TAFI by plasmin . These residues are lysine 268, serine 272, arginine 276, threonine 147, 
and phenylalanine113. Lysine 268, serine 272, arginine 276 are important exclusively in 
plasmin binding to TAFI, while the rest of these residues are implicated in activation of 
TAFI by both plasmin and thrombin [100]. The fact that not all of these residues are 
lysines is explained by the fact that the mutations were made on the basis of binding sites 
mapped for antibodies against TAFI that specifically impaired activation by plasmin or 
thrombin; the effect of the mutations on recognition by these proteases may be due to 
local alterations in protein structure. Figure 4-1a exhibits the positioning of these residues 
in three-dimensional model of TAFI. Since variants K211Q/K212Q, R320A/K324A, and 
K306A exhibit a larger Km (app), there is a possibility that these residues participate in 
plasmin binding to TAFI. Figure 4-1b displays the positioning of these residues in 
relation to each other, while Figure 4-1 c, d, and e display the positioning of these 
residues in relation to the residues that have been shown to participate in the binding of 
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TAFI to plasmin. Although these K211, K212, R320, K324, and K306 are not positioned 
in close proximity to the residues that have been implicated in plasmin in plasmin 
binding, nor are the previously-described residues important for plasmin binding, in 
respect to each other (Fig 4-1). From Fig 4-1 it is also evident that K211, K212, R320, 
K324, and K306 are exposed charged residues that could potentially interact with the 
kringle domains of plasmin.  
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 Figure 4-1. Location of residues implicated in decreased activation of TAFI by 
plasmin. Images were generated using Cn3D software (pdb file:3D66 of human TAFI) 
Activation peptide is demonstrated in cyan, catalytic domain is in purple. TAFI cleavage 
site by thrombin and plasmin, Arg92, is represented in red, indicated with an arrow. a) 
Location of residues previously reported to be critical for plasmin binding to TAFI 
(yellow). b) Location of the residues mutated in variants that exhibit lower affinity to 
plasmin (green). c)-e) Location of each individual variant in b) in relation to residues in a) 
 
                       
               a) 
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                         d)                              Lys 306 
 
e)                                                                 Arg320/Lys324
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There was not complete concordance between impaired heparin binding and an 
effect on heparin-accelerated activation by plasmin. The variants K212A, K327A, and 
K327A/R330A show impaired heparin binding, yet essentially normal responses to 
heparin in the plasmin activation assay. The K211Q/K212Q and R320A/K324A variants 
did exhibit a lower fold difference in kcat/KM in the presence or absence of heparin, which 
could potentially be due to the lower affinity of these variants for heparin. Notably, The 
K211Q/K212Q, R320A/K324A, and K306A variants were also impaired in respect to 
plasmin activation, when compared to wild-type TAFI, which complicates interpretation 
of the results. Is the defect in heparin binding responsible for the lower stimulation of 
activation, or does the apparently impaired interaction of the variants with plasmin impair 
the ability of heparin to have its stimulatory effect? In the case of thrombin inhibition by 
antithrombin, heparin catalyzes this reaction by binding to both thrombin and 
antithrombin [22,85]. It is highly likely that heparin binds to both plasmin and TAFI, thus 
eliciting its accelerating effect on TAFI activation by plasmin. In that case, impaired 
binding of TAFI to plasmin, would also affect heparin binding to TAFI. To further 
investigate this possibility, a truncated form of plasmin can be used. Microplasmin lacks 
all 5 kringles, but has an active catalytic domain [98], which, in theory, could still activate 
TAFI. This approach may give an insight on whether heparin can still elicit its catalyzing 
effect on plasmin-mediated activation of TAFI in a kringle-independent manner.  
In addition to the above mentioned variants, a number of additional variants were 
studied in respect to plasmin activation in the presence or absence of heparin. These 
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variants are K59A, R12A, R15A, S316A, and S249A/S251A. Variants K59A, R12A, and 
R15A were pursued based on the report that a number of sulfates were bound to the 
exposed charged residues in the pro-domain [51]. The identity of these residues was not 
provided, therefore, we used the Cn3D software (pdb:3D66) to explore the three-
dimensional shape of the TAFI molecule, and to identify exposed charged residues in the 
pro-domain.  Variants S316A, S249A/S251A were pursued based on another report of the 
TAFI crystal structure, where sulfates were found to be associated with these residues 
[52].The data for these variants are preliminary, and therefore is reported in the 
Appendix; however, the replacement of these residues with an alanine residue did not 
abolish the accelerating effect of heparin on TAFI activation. Further characterization of 
these variants is required to determine if the accelerating effect of heparin is reduced to a 
certain degree, in comparison to the wild-type TAFI. 
4.4 Thermal Stability of TAFI variants in the Presence and Absence of Heparin.  
 Heparin, has been shown to increase thermal stability of TAFIa [43]. Mao and 
coworkers established that half-life of TAFI at 25˚C was increased from 74 min to 170 
min in the presence of TAFI [43]. Although they did not examine the role of heparin on 
the stability of TAFIa at body temperature, we expected to see a similar effect of heparin 
on the stability of TAFIa at 37˚C.  Indeed, it was found that presence of heparin increased 
the half-life of the wild-type enzyme from 6.41±0.53 minutes to 10.8 ±0.11 minutes. To 
further examine the contribution of various residues on the stability of TAFIa in the 
presence and absence of heparin, we subjected the variants in question to the same assay. 
As expected, the majority of the mutations in the instability region decreased the stability 
of TAFIa both in the presence and absence of heparin, when compared to the wild-type 
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enzyme. Stability of the variant H308F was similar to the wild-type TAFIa, within 
experimental error. The variant R320A/K324A was found to be more stable in the 
absence of heparin, when compared to the wild-type TAFIa. The stability of TAFIa 
depends on the dynamics of the instability region, and this double mutation could 
potentially reduce the movement of this region, thus increasing stability. Lysine 324 is 
also neighbouring threonine 325, which is the site of a naturally occurring single 
nucleotide polymorphism. When isoleucine is substituted for threonine at this position, 
the half-life of TAFIa is increased from ~8 min to ~15 min [55]. Therefore, it is possible 
that the substitution of a charged residue with an uncharged alanine could potentially 
have a stabilizing effect. Variant K327A, K327A/R330A, and K212A seem to be slightly 
less stable in the presence and absence of heparin. When examining the effect of heparin 
on the half-lives of all of the above variants, half-life fold increase is the lowest for 
K327A, K327A/R330A, and K212A, and R320A/K324A. Half-life fold increase of these 
variants in the presence of heparin is 1.3, compared to the wild-type enzyme, where the 
half-life fold increase is 1.7. Therefore, these residues could potentially be important in 
the modulation of TAFIa stability by heparin. As with the plasmin activation experiment, 
there was no perfect agreement between the heparin binding data and the stability data. 
While all of the variants with impaired stabilization by heparin also show reduced binding 
to the heparin column, the K211Q/K212Q variant shows nearly normal stabilization by 
heparin. 
 As in the case of plasmin activation, a number of variants were introduced in the 
later stages of this study. Since variant S316A is in the instability region, while 
S249A/S251A is close to the instability region, the effect of heparin on the thermal 
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stability was analyzed. Preliminary results are reported in the Appendix. Although, the 
data is preliminary, there was a clear effect of heparin on the stability of TAFIa in both 
variants. Further studies will be needed to examine if the stability increase in the presence 
of heparin is reduced compared to the wild-type enzyme. 
4.5 Conclusion 
In the current study we set out to examine the effect of heparin binding on the 
plasmin-mediated TAFI activation and thermal stability of TAFIa. A number of TAFI 
residues suspected in the participation of heparin binding were mutated with an ultimate 
goal of determining variants that are resistant to heparin binding. Such variants would be 
useful for assessing the importance of heparin modulation of TAFI activation and TAFIa 
stability, for example in the setting of anticoagulation with heparin or in the presence 
extracellular matrix. Although variants that are completely resistant to heparin binding 
were not identified, we established a number of variants that are moderately impaired in 
respect to heparin binding, and one, R320A/K324A that is very nearly completely 
impaired in heparin binding. In addition, there was a strong, but not absolute, relationship 
between the degree of impairment in heparin binding and reduction in activation or 
stabilization by heparin.  Therefore, it is reasonable to conclude that there are multiple 
sites on TAFI for heparin binding, and that heparin binding at these different sites may be 
important for different functions of heparin in respect to TAFI. Variants such as K211A, 
K327A, and K327A/R330A displayed reduced binding to the heparin-agarose column 
(dramatically so in the case of K327A/R330A), while still showing similar kinetic 
parameters in respect to plasmin-mediated activation. The same variants exhibited the 
lowest difference in the half-life of TAFIa in the presence and absence of heparin. 
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However, these variants with the addition of K211Q/K212Q eluted from the heparin-
agarose column in two peaks, which could either be the result of lower affinity (for 
example because of the elimination of one heparin binding site), or presence of two 
glycoforms of TAFI. Different glycoforms may exhibit differential affinity for heparin. 
Further studies are required to analyze the role of potential differential glycosalation on 
the binding of these variants to heparin. Since the activation parameters were not affected 
by the reduced affinity to heparin for some variants, these residues may play a role in the 
stabilization of TAFI in the presence of heparin. Variants K306A, K211Q/K212Q, and 
R320A/K324A seem to exhibit both a reduced effect of heparin on the activation of TAFI 
by plasmin, as well as lower affinity for plasmin, due to large Km (app) of this variants. 
Further investigation is required to establish whether the lower affinity of these variants 
to plasmin interferes with proper TAFI binding to heparin, and prevents heparin from 
eliciting its accelerating function.  It will be interesting to find out if combining sets of 
mutations, such as R320A/R324A and K327A/R330A is able to yield a variant of TAFI 
that is resistant to both heparin-mediated stimulation of activation by plasmin, as well as 
stabilization. 
Although we identified certain residues that may participate in the binding of 
TAFI to heparin, there are still a number of remaining questions. Since both activation of 
TAFI and thermal stability of TAFIa will ultimately affect the antifibrinolytic potential of 
TAFI, the next step would be to determine the effect of heparin on the antifibrinolytic 
effect of TAFI, and to analyze the contribution of the studied residues on the attenuation 
of fibrinolysis in the presence and absence of heparin.  
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Another issue that still remains unresolved is the contribution of the accelerated 
activation of TAFI by plasmin versus the increased stability of TAFI in the presence of 
heparin. Mao and coworkers suggested that heparin binding changes TAFI conformation, 
making it a better substrate for plasmin activation [43]. However, once activated, TAFI is 
extremely unstable. Heparin, however, also stabilizes TAFIa. As a result, heparin 
contributes to increased effective TAFIa concentration in both ways. To distinguish 
between the two functions of heparin, and to determine the relative contribution of these 
functions on the concentration of TAFIa, a stable TAFI variant can be used. Recombinant 
TAFI variant, with mutations S305C, and T329I, and an isoleucine at the 325 position, 
has a half-life of 70 min [54]. Since this variant is more stable, the increase in TAFIa 
activity within a clot will mostly be a result of accelerated activation of TAFI by plasmin. 
Alternatively, we could use a mutant such as K327A that is susceptible to heparin 
acceleration of activation but not heparin stabilization. 
Finally, to understand the full effect of heparin on the TAFI pathway, its 
contribution on TAFI activation by thrombin/thrombomodulin complex has to be 
investigated. It was reported that presence of heparin actually reduced activation by 
thrombin/thrombomodulin complex [44]. However, it is not known whether heparin 
binding to TAFI prevents binding of the thrombin/thrombomodulin complex to TAFI, or 
if heparin binds directly thrombin/thrombomodulin complex. To investigate that, TAFI 
variants that are resistant to heparin binding would have to be used. 
Overall, the goal of this study was to identify TAFI residues that participate in 
heparin binding, and their contribution on the plasmin-mediated activation and stability of 
TAFI. Understanding of the heparin function in respect to TAFI would provide answers 
for the overall picture of the role of TAFI in hemostasis of a healthy individual, as well as 
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that of an individual that is undergoing anticoagulation with heparin or a related 
compound. The anticoagulant properties of heparin may be antagonized by the TAFI 
pathway. Understanding the binding sites, and possibly length requirements of heparin-
like molecule in respect to TAFI could give rise to a development of a treatment that is 
unable to either stabilize TAFI, or accelerate plasmin-mediated activation of TAFI, or 
both. Similar approach was taken during the development of the drug Fondaparinux 
which exclusively stimulates inhibition of FXa by antithrombin, while having no effect 
on inhibition of other proteases of the coagulation pathway. This exclusivity is due to the 
fact that a short sequence, present in this heparin-like molecule, is sufficient to stimulate 
inhibition of FXa but not other targets, such as thrombin [85]. This potentially could be 
the case with plasmin-mediated TAFI activation. 
Understanding glycosaminoglycan binding to TAFI is extremely important under 
both natural and heparin treatment-induced circumstances. Understanding TAFI 
interaction with heparin, heparan sulfate, and other glycosaminoglycans will provide us 
with more insight into the contribution of thrombin, the thrombin/thrombomodulin 
complex, and plasmin on the localized concentration of TAFIa. In the case of the 
anticoagulant treatments with heparin-like drugs, understanding the interaction of heparin 
with TAFI and the consequence of this interaction will aid in the development of more 
tailored and targeted drugs. 
  
 
 
 
 
69 
 
References 
1. Mann KG. Thrombosis: theoretical considerations. Am J clinical Nutrition 1997; 
65: 1657s-1664s. 
2. Dahlback B. Blood coagulation and its regulation by anticoagulant pathways: 
genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med 2005; 
257: 209-223 
3. Nesheim M. Thrombin and fibrinolysis. Chest. 2003; 124 (3Suppl):33S-
9S.Review. 
 
4. Rasche H. Haemostasis and thrombosis: an overview.  European Heart Journal 
Supplement 2001; 3 (Supplement): Q3-Q7 
5. Offermans S. Activation of platelet function through G protein-coupled receptors. 
Circulation Research.2006;99:1293-1304 
6. Mason RG, Mohammad SF, Chuang HY, Richardson PD. The adhesion of 
platelets to subendothelium, collagen and artifilial surfaces. Semin Thromb 
Hemost. 1976;3(2):98-116. 
7. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI  the central 
receptor? Blood. 2003;102(2):449-461. 
 
8. Zucker MB, Nachmias VT. Platelet activation. Arteriosclerosis. 1985;5 (1):2-18. 
 
9. Ruggeri MR. Platelets in atherothrombosis. Nature Medicine 2002;8:1227-1234 
10. Lentz BR. Exposure of platelet membrane phosphatidylserine regulates blood 
coagulation. Prog Lipid Res. 2003;42(5):423-438. 
 
 
70 
 
 
11. Nemerson Y. Tissue factor and hemostasis. Blood. 1988 ;71(1):1-8.  
 
12. Rosing J, Tans G, Givers-Riemslag JW, Zwaal RF, Hemker HC. The role of 
phospholipids and factor Va in the prothrombinase complex.Journal of Biological 
Chemistry 1980;255:274-283 
 
13. Naito K, Fujikawa K. Activation of human blood coagulation factor XI 
Independent of factor XII. The Journal of Biological Chemistry 1991;266:7353-
7358 
14. Gomez K, Bolton-Maggs P. Factor XI deficiency.Haemophilia 2008;14:1183-
1189 
15. Mackman N. Role of the extrinsic pathway of blood coagulation in hemostasis 
and thrombosis. Journal of the American Heart Association 2007; 27: 1687-1693 
16. Tanaka KA. Blood coagulation: Hemostasis and thrombin regulation. Anesthesia 
and Analgesia 2009;108:1433-1466 
17. Crawley JTB, Zanardelli S, Chion CKCK, Lane DA. The central role of thrombin. 
Journal of Thrombosis and Haemostasis 2007;5:95-101 
18. Pixley RA, Schapira M, Colman, R. The regulation of human factor XIIa by 
plasma protenase inhibitors. The Journal of Biological Chemistry 1985;260:1723-
1729 
19. Wiebe EM, Stafford AR, Fredenburgh JC, Weitz JI. Mechanism of catalysis of 
inhibition of factor IXa by antithrombin in the presence of heparin or 
pentasaccharide. The Journal of Biological Chemistry 2003;37:35767-35774 
 
 
71 
 
20. Dahlbäck B. Blood coagulation. Lancet. 2000 May 6;355(9215):1627-32 
 
21. Weitz JL, Hudobs M, Massel D, Maraganore J, Hirsh. Clot-bound thrombin is 
protected from inhibition by heparin-antithrombin III but is susceptible to 
inactivation by antithrombin III-independent inhibitors.Journal of Clinical 
Investigation 1990;86;385-391 
 
22. Rosenburg RD, Damus PS. The purification and mechanism of action of human 
antithrombin-heparin cofactor. The Journal of Biological Chemistry 
1973;248:6490-6505 
 
23. Jordan RE, Oosta GM, Gardner WT, Rosenburg RD. Kinetics of hemostatic 
enzyme-antithrombin interactions in presence  f low molecular weight heparin. 
The Journal of Biological Chemistry 1980;255:10081-10090 
 
24. Esmon CT. The protein C pathway. Chest 2003;124(3)supplement:26S-32S 
 
25. Cesarman-Maus G, Hajjar KA. Molecular mechanism of fibrinolysis.  British 
Journal of Haematology 2005;129:307-321 
 
26. Lucore CL, Sobel BE. Interactions of tissue-type plasminogen activator with 
plasma inhibitors and their pharmacologic implications. Circulation 1988;77:660-
669 
 
 
72 
 
27. Collen D, Wiman B. Fast-acting plasmin inhibitor in human plasma. Blood. 
1978;51(4):563-569 
28. Weisel JW. Fibrinogen and fibrin. Adv Protein Chem. 2005;70:247-99. 
 
29. Suenson E, Lützen O, Thorsen S. Initial plasmin-degradation of fibrin as the basis 
of a positive feed-back mechanism in fibrinolysis. Eur J Biochem. 
1984;140(3):513-522. 
 
30. Bajzar L, Nesheim M. The effect of activated protein C on fibrinolysis in 
             cell-free plasma can be attributed specifically to attenuation of prothrombin 
             activation. J Biol Chem. 1993 Apr 25;268(12):8608-8616 
 
31. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a 
             thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1995;270:14477- 14484. 
 
32. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the 
mechanism of inhibition of fibrinolysis by activated thrombin-activable 
fibrinolysis inhibitor. J Biol Chem. 1998;273(42):27176-27181 
 
33. Mosnier LO, Bouma NB. Regulation of fibrinolysis by Thrombin Activable 
Fibrinolysis Inhibitor, and unstable carboxypeptidase B that unites the pathways 
of coagulation and fibrinolysis. Arteriosclerosis , Thrombosis, and Vascular 
Biology 2006; 26:2445-2453 
 
 
 
73 
 
34. Eaton DL, Malloy BE, Tsai SP, Henze W, Drayna D. Isolation, molecular cloning, 
and partial characterization of a novel carboxypeptidase B from human plasma. 
The Journal of Biological Chemistry 1991; 266; 21833-21838 
 
35. Schadinger SL, LIN JHH, Garand M, Boffa MB. Secretion and antifibrinolytic 
function of thrombin-activatable fibrinolysis inhibitor from human platelets. 
Journal of Thrombosis and Haemostasis 2010;8;2523-2529 
 
36. Lin JHH, Garand M, Zagorac B, Schadinger SL, Scipione C, Koschinsky ML, 
Boffa MB. Identification of human thrombin-activatable fibrinolysis inhibitor in 
vascular and inflammatory cells. Thrombosis and Haemostasis 2011;105;999-
1009 
 
37. Hori Y, Nakatani K, Morioka K, Katsuki A, Gabazza EC, Yano Y, Nobori T, 
Adachi Y, Sumida Y. Insulin enhanced thrombin-activable fibrinolysis inhibitor 
expression through PI3 kinase/Akt pathway. International Journal of Molecular 
Medicine 2005; 15: 265-268 
 
38. Valnickova Z, Christense T, Skottrup P, Thogersen IB, Hojruo P, Enghild JJ. 
Post-Translational modifications of human Thrombin-Activatable Fibrinolysis 
Inhibitor (TAFI): Evidence for a large shift in the isoelectric point and reduced 
solubility upon activation. Biochemistry 2006;45:1525-1535 
 
 
 
74 
 
39. Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant Thrombin-
activable Fibrinolysis Inhibitor (TAFI) and activated TAFI compared with to 
glycosylation, thrombin/thrombomodulin-dependant activation, thermal stability, 
and enzymatic properties.The Journal of Biological Chemistry 1998;273:2127-
2135 
 
40. Marx PF, Brondijk TH, Plug T, Romijn RA, Hemrika W, Meijers JC, Huizinga 
EG.Crystal structures of TAFI elucidate the inactivation mechanism of activated 
TAFI: a novel mechanism for enzyme autoregulation. Blood. 2008;112(7):2803-9. 
 
41. Bajzar L, Morser J, Nesheim . TAFI, or plasma carboxypeptidase B, couples the 
coagulation and fibrinolytic cascades though the thrombin-thrombomodulin 
complex. The Journal of Biological Chemistry 1996;271:16603-16608 
42. Boffa MB, Nesheim ME, Koschinsky ML. Thrombin activable fibrinolysis 
inhibitor(TAFI): molecular genetics of an emerging potential risk factor for 
thrombotic disorders. Curr Drug Targets Cardiovasc Haematol Disord. 2001 
Dec;1(2):59-74. 
 
43. Mao SS, Carolyn MC, Wood T, Shafer JA, Gardell SJ. Characterization of 
plasmin-mediated activation of plasma procarboxypeptidase B.  The Journal of 
Biological Chemistry 1999;274:35046-35052 
44. Binette TM, Taylor FB Jr, Peer G, Bajzar L. Thrombin-thrombomodulin connects 
 
 
75 
 
 coagulation and fibrinolysis: more than an in vitro phenomenon. 
Blood.2007;110(9):3168-75. 
 
45. Von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. 
             Thrombin-mediated activation of factor XI results in a thrombin-activatable 
fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest. 1997;99  
(10):2323-7. 
 
46. Minnema MC, Friederich PW, Levi M, von dem Borne PA, Mosnier LO, Meijers 
JC, Biemond BJ, Hack CE, Bouma BN, ten Cate H. Enhancement of rabbit 
jugular vein  thrombolysis by neutralization of factor XI. In vivo evidence for a 
role of  factor XI as an anti-fibrinolytic factor. J Clin Invest. 1998;101(1):10-4.  
47. Vercauteren E, Emmerechts J, Peeters M, Hoylaerts MF, Declerck PJ, Gils 
A.Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal 
antibody in a mouse thromboembolism model. Blood. 2011 Apr 28;117(17):4615-
22 
 
48. Lindhal U, Kusceh-Gullberg M, Kjellen L. Regulated diversity of Heparan 
Sulfate. The Journal of Biological Chemistry 1998;273:24979-24982 
 
49. Boffa MB, Bell R, Stevens WK, Nesheim ME. Roles of thermal stability and 
proteolytic cleavage in regulation of activated Thrombin-activable Fibrinolysis 
inhibitor. The Journal on Biological Chemistry 2000;275:12868-12878 
 
 
76 
 
50. Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant thrombin-
activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect 
to glycosylation, thrombin/thrombomodulin-dependent activation, thermal 
              stability, and enzymatic properties. J Biol Chem. 1998;273(4):2127-2135. 
 
51. Anand K, pallares I, Valnikova Z, Chrostensen T, Vendrell J, Wendt KU, 
Schreuder HA, Enghil JJ, Aviles FX. The crustal structure of Thrombin-
Activatable Fibrinolysis Inhibitor (TAFI) provides the structural basis for its 
intrinsic activity and the short half-life of TAFIa. The Journal of Biological 
Chemistry 2008;283:29416-29423 
 
52. Sanglas L, Valnikova Z, Arolas JL, Pallares I, Guevara T, Sola M, Kristensen T, 
Enghild JJ, Aviles FX, Gomis-Ruth FX. Structure of activated Thrombin-
Activatable Fibrinolysis Inhibitor, a molecular link between coagulation and 
fibrinolysis. Molecular Cell 2008;31:598-606 
53. Marx PF, Hackeng TM, Dawson PE, Griffin JH, Meijers JCM, Bouma BN. 
Inactivation of active Thrombin-activable Fibrinolysis Inhibitor takes place by a 
process that involves conformational instability rather than proteolytic cleavage. 
The Journal of Biological Chemistry 2000;275:12410-12415 
54. Ceresa E, Peeters M, Declerck PJ, Gils A. Announcing a TAFIa mutant with a 
              180-fold increased half-life and concomitantly a strongly increased 
              antifibrinolytic potential. J Thromb Haemost. 2007;5(2):418-20. 
 
 
 
77 
 
55. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two 
              naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially 
              with respect to thermal stability and antifibrinolytic activity of the enzyme. J  
              Biol Chem. 2002;277(2):1021-30. 
 
56. Walker JB, Bajzar L. The intrinsic threshold of the fibrinolytic system is 
              modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic 
              effect of activated thrombin-activable fibrinolysis inhibitor is masked by its 
              instability. J Biol Chem. 2004;279(27):27896-904 
 
57. Leurs J, Nerme V, Sim Y, Hendriks D. Carboxypeptidase U (TAFIa) prevents 
lysis from proceeding into the propagation phase through a threshold-dependent 
            mechanism. J Thromb Haemost. 2004;2(3):416-23 
 
58. Schneider M, Nesheim M. Reversible inhibitors can both promote and inhibit 
fibrinolysis. Journal of Thrombosis and Haemostasis.2003;1:147-154 
59. Willemse JL, Heylen E, Nesheim ME, Hendriks DF. Carboxypeptidase U 
(TAFIa): a new drug target for fibrinolytic therapy? J Thromb Haemost. 
2009;7(12):1962-71. 
60. Development pipeline at 31 January 2008. Retrieved September 15,2012, from 
http://www.astrazeneca-
annualreports.com/2007/business_review/resources/development_pipeline.asp 
 
 
 
78 
 
61. Alkjaersig N, Fletcher AF, Sherry S. The mechanism of clot dissolution by 
plasmin. Journal of Clinical Investigation 1959;38:1086-1095 
 
62. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of 
plasminogen by human tissue plasminogen activator. Role of fibrin.J Biol 
Chem.1982;257(6):2912-9. 
 
63. Suenson E, Lützen O, Thorsen S. Initial plasmin-degradation of fibrin as the basis 
of a positive feed-back mechanism in fibrinolysis.Eur J Biochem. 
1984;140(3):513-22.  
 
64. Violand BN, Castellino FJ. Mechanism of the urokinase-catalyzed activation of  
              human plasminogen. J Biol Chem. 1976 Jul 10;251(13):3906-12. 
 
65. Lee KN, Lee CS, Tae WC, Jackson KW, Christiansen VJ, McKee PA. 
Crosslinking of alpha 2-antiplasmin to fibrin. Ann N Y Acad Sci. 2001;936:335-9. 
 
66. Schneider M, Nesheim M. A study of the protection of plasmin from antiplasmin 
inhibition within an intact fibrin clot during the course of clot lysis. J BiolChem. 
2004;279:13333-9. 
 
67. Kolev K, Tenekedjiev K, Komorowicz E, Machovich R. Functional evaluation of 
              the structural features of proteases and their substrate in fibrin surface 
              degradation. J Biol Chem. 1997;272(21):13666-13675 
 
 
79 
 
 
 
68. Syrovets T, Simmet T. Novel aspects and new roles for the serine protease 
              plasmin. Cell Mol Life Sci. 2004;61(7-8):873-885.  
 
69. Novokhatny V. Structure and activity of plasmin and other direct thrombolytic  
              agents. Thromb Res. 2008;122 Suppl 3:S3-8. 
 
70. Wiman B, Wallén P. On the primary structure of human plasminogen and 
plasmin. Purification and characterization of cyanogen-bromide fragments. Eur J 
Biochem.1975 Sep 15;57(2):387-394. 
 
71. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of 
             plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 
            1982 Mar 25;257(6):2912-2919. 
 
72. Hervio LS, Coombs GS, Bergstrom RC, Trivedi K, Corey DR, Madison EL. 
Negative selectivity and the evolution of protease cascades: the specificity of 
plasminfor peptide and protein substrates. Chem Biol. 2000;7:443-453. 
 
73. Backes BJ, Harris JL, Leonetti F, Craik CS, Ellman JA. Synthesis of 
positional-scanning libraries of fluorogenic peptide substrates to define the 
extended  substrate specificity of plasmin and thrombin. Nat Biotechnol. 
2000;18:187-193.  
 
 
80 
 
 
 
74. Miah MF, Boffa MB. Functional analysis of mutant variants of 
             thrombin-activatable fibrinolysis inhibitor resistant to activation by thrombin 
              or plasmin. J Thromb Haemost. 2009;7(4):665-72. 
 
75. Hileman RE, Fromm JR, Weiler JM, Linhardt RJ. Glycosaminoglycan-protein 
             interactions: definition of consensus sites in glycosaminoglycan binding 
             proteins. Bioessays. 1998;20(2):156-67. 
 
76. Smits NC, Robbesom AA, Versteeg EM, van de Westerlo EM, Dekhuijzen PN, 
van Kuppevelt TH. Heterogeneity of heparan sulfates in human lung. Am J Respir 
Cell Mol Biol. 2004;30(2):166-173. 
 
77. Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed 
Engl.2002;41:391-412. 
78. Rabenstein DL. Heparin and heparan sulfate: structure and function. Nat Prod 
Rep. 2002;19:312-331. 
 
79. Raman R, Sasisekharan V, Sasisekharan R. Structural insights into biological 
roles of protein-glycosaminoglycan interactions. Chem Biol. 2005;12:267-77 
 
80. Fromm JR, Hileman RE, Caldwell EE, Weiler JM, Linhardt RJ. Differences in the 
interaction of heparin with arginine and lysine and the importance of these basic 
 
 
81 
 
amino acids in the binding of heparin to acidic fibroblast growth factor. Arch 
Biochem Biophys. 1995;323:279-287 
 
81. Maaroufi RM, Jozefowicz M, Tapon-Bretaudière J, Fischer AM. Mechanism of 
              thrombin inhibition by antithrombin and heparin cofactor II in the presence of 
              heparin. Biomaterials. 1997;18(3):203-211. 
 
82. Lindahl U, Bäckström G, Thunberg L, Leder IG. Evidence for a 3-O-sulfated D-
glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl 
Acad Sci U S A. 1980;77:6551-6555. 
 
83. Petitou M, Duchaessoy P, Driquez PA, Jaurand G, Herault JP, Lormeau JC, 
Bouckel, CAA, Herbert JM. First synthetic carbohydrates with the full 
anticoagulant properties of heparin. Angewandte Chemie International Edition 
1998;37:3009-3014 
 
84. Choay J, Petitou M, Lormeau JC, Sinaÿ P, Casu B, Gatti G. Structure-
activityrelationship in heparin: a synthetic pentasaccharide with high affinity for 
antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res 
Commun. 1983;116:492-9. 
 
 
85. Bauer KA. New pentasaccharides for prophylaxis of deep vein thrombosis: 
              pharmacology. Chest. 2003;124(6 Suppl):364S-370S. 
 
 
82 
 
 
 
86. Cardin AD, Weintraub HJ. Molecular modeling of protein-glycosaminoglycan 
             interactions. Arteriosclerosis. 1989;9:21-32. 
 
87. Sobel M, Soler DF, Kermode JC, Harris RB. Localization and characterization ofa 
heparin binding domain peptide of human von Willebrand factor. J Biol            
Chem.1992;267:8857-8862. 
 
88. Margalit H, Fischer N, Ben-Sasson SA. Comparative analysis of structurally 
defined heparin binding sequences reveals a distinct spatial distribution of 
             basic residues. J Biol Chem. 1993 Sep 15;268(26):19228-19231. 
 
89. McRae SJ, Ginsberg JS. Initial treatment of venous thromboembolism. 
             Circulation. 2004 Aug 31;110 
 
90. Ludwig RJ. Therapeutic use of heparin beyond anticoagulation. Curr Drug Discov 
Technol. 2009 Dec;6:281-9. 
 
91. Franchini M, Veneri D.Heparin-induced thrombocytopenia. Recenti Prog 
Med.2005;96:433-5. 
 
 
 
83 
 
92. Oie CI, Olsen R, Smedsrød B, Hansen JB. Liver sinusoidal endothelial cells are 
the principal site for elimination of unfractionated heparin from the circulation. 
Am J Physiol Gastrointest Liver Physiol. 2008;294:G520-8. 
 
93. Harris EN, Weigel JA, Weigel PH. The human hyaluronan receptor for 
endocytosis (HARE/Stabilin-2) is a systemic clearance receptor for heparin. J Biol 
Chem. 2008;283:17341-50. 
94. Lindahl U, Höök M. Glycosaminoglycans and their binding to biological 
macromolecules. Annu Rev Biochem. 1978;47:385-417. 
 
95. Linhardt RJ, Gunay NS. Production and chemical processing of low molecular 
weight heparins. Semin Thromb Hemost. 1999;25 Suppl 3:5-16.  
 
96. Dextran sulphate-a synthetic analogue of heparin C. R. Ricketts Biochem J. 1952; 
51(1): 129–133.   
 
97. Olson ST, Frances-Chmura AM, Swanson R, Björk I, Zettlmeissl G. Effect of 
individual carbohydrate chains of recombinant antithrombin on heparin affinity 
and on the generation of glycoforms differing in heparin affinity. Arch Biochem 
Biophys. 1997;341(2) :212-21 
 
98. Komorowicz E, Kolev K, Machovich R. Fibrinolysis with des-kringle derivatives 
of plasmin and its modulation by plasma protease inhibitors. Biochemistry. 
1998;37(25):9112-8. 
 
 
84 
 
 
99. Law RH, Sofian T, Kan WT, Horvath AJ, Hitchen CR, Langendorf CG, Buckle 
AM,Whisstock JC, Coughlin PB. X-ray crystal structure of the fibrinolysis 
inhibitor alpha2-antiplasmin. Blood. 2008;111(4):2049-52 
100. Mishra N, Vercauteren E, Develter J, Bammens R, Declerck PJ, GilsA. 
Identification and characterisation of monoclonal antibodies that impair the 
activation of human thrombin activatable fibrinolysis inhibitor through different 
mechanisms. Thromb Haemost. 2011;106(1):90-101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
85 
 
Appendix 
This section summarizes the optimization process for quantification of heparin binding to 
TAFI. This section also summarizes the preliminary results for plasmin-mediated 
activation and thermal stability of recently developed variants. These variants were 
pursued in the later stages of this study and thus complete characterization of these 
variants could not be completed. The rationale for the development of variants K59A, 
R15A was based on the fact that in a crystal structure of bovine TAFI, a number of 
sulfates were bound to charged residues in the pro-domain [1]. Due to the fact that 
heparin binding in the pro-domain would not explain the increased stability of TAFI in 
the presence of heparin, Anand and coworkers suggested that the pro-domain is not the 
most likely heparin binding region. However, binding of heparin to the pro-domain can 
have other consequences in respect to TAFI function. Although, the identity of these 
residues was not disclosed, using a crystal structure of human TAFI (pdb: 3D66) we 
identified residues R15A and K59A to be exposed, and thus they could potentially 
facilitate binding to heparin. Another report of a bovine TAFI crustal structure, in the 
presence of sulfates, resulted in the development of S316A and S249A/S251A [2]. 
Preliminary thermal stability experiments were only done on variants S316A and 
S249A/S251A since the variants with the mutation in the pro-domain are not likely to 
have an effect on the thermal stability in respect to heparin binding. 
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A-1 Materials and Methods 
Analysis of the dissociation constant between heparin-agarose and TAFI  
20µL of Heparin-agarose resin (Sigma-Aldrich) or 4-% agarose resin (MPbiomedicals) 
was incubated with increasing concentrations of TAFI (0.02 µM-0.14 µM) for 30 min in 
HBS buffer. The mixture was then centrifuged at 3000 rpm, and the supernatant was 
removed. The supernatant is thought to contain unbound TAFI. To analyze the 
concentration of unbound TAFI versus the concentration of total TAFI, samples were first 
subjected to the western blot analysis. Using a standard curve for each experiment, band 
analysis was used to quantify the concentration of unbound TAFI, and thus the 
concentration of bound TAFI, through subtraction. The values were used to plot total 
TAFI concentration, or unbound TAFI concentration versus bound TAFI concentration. A 
scatchard plot was also constructed. Due to the scatter in the points, a dissociation 
constant could not be obtained. The experiment was repeated a number of times, varying 
either the concentrations of TAFI, or the volume of the resin, without an improvement in 
the quality of the data. We then investigated whether a different method of TAFI 
detection would be more appropriate for this experiment, and thus used enzyme-linked 
immunosorbent assay (ELISA). ELISA was carried out as follows. The binding 
experiment was performed in the same manner as above, samples representing unbound 
TAFI or total TAFI  were diluted in coating buffer (0.012M sodium carbonate , 0.028M 
sodium  bicarbonate pH 9.6) and applied on polystyrene 96-well plates (Corning) 
overnight at 4˚C. The wells were washed 3 times with phosphate buffered saline (PBS) 
(137 mM NaCl, 1,4 mM KH2PO4, 2.7 mM KCl, 3mM Na2HPO4 pH 7.4) containing 
0.1%(v/v)Tween-20.The wells were blocked with blocking solution (PBS containing 3% 
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(w/v) bovine serum albumin) for 2 hours at room temperature. The wells were washed 
again, and then incubated with 1 μg/mL primary polyclonal sheep anti-TAFI antibody 
(Affinity Biologicals) in dilution buffer (HBS containing 1% (w/v) bovine serum 
albumin) on a shaker for 1 hour at room temperature.After another wash of the wells, they 
were incubated with 1 μg/mL secondary hydrogen peroxide-conjugated anti-sheep IgG 
(Thermo Scientific) in the dilution buffer,on a shaker for 1 hour at room temperature. The 
wells were then washed again and colour development solution was then applied, 
consisting of phenylenediamine dihydrochloride tablet (Sigma-Aldrich) dissolved in a 12 
mL of substrate buffer (0.05 M citric acid/sodium-phosphate buffer, pH 5.0); each well 
received 100 µL of the solution. Colour development was stopped by the addition of 50 
µL of 2M H2SO4 and the absorbance of each well was measured at 490 nm (and corrected 
for absorbance at 560 nm) to quantify TAFI present in each well. The total TAFI wells 
were used as a standard curve. The dilution of the sample in coating buffer varied 
between 2µL-50µL of the sample in total volume of 100µL of coating buffer. The best 
standard curve was obtained with the lowest range of 2µL.Calculations of bound and 
unbound TAFI were done in the same manner as described above.  
 
 
A-2 Results 
 
A-2.1 Analysis of the dissociation constant between heparin-agarose and TAFI 
Following the elution experiment of TAFI binding to heparin agarose, we set out to 
quantify the binding affinity of heparin to TAFI, employing a ligand binding assay. After 
varying different aspects of the experimental approach (volume of the resin, concentration 
of TAFI, and the detection technique), the dissociation constant could not be determined, 
as there was no clear relationship between the increasing concentration of TAFI, and the 
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concentration of bound TAFI. Figure A-1 c) and d) shows that there was no linear 
relationship, and the slope, which is used to determine the dissociation constant, could not 
be obtained. Due to time constraints, this experiment could not be further optimized, and 
it cannot be excluded that the dissociation constant can be quantified with this method. 
However, since the number of binding sites and the contribution of these sites to the 
binding of heparin to TAFI are unknown, this method may not result in a linear scatchard 
plot.   
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Figure A-1. Quantitative analysis of the dissociation constant between heparin-
agarose and TAFI. Panels a) and b) represent the concentration of bound TAFI as a 
function of total TAFI for WT and variant R320A/K324A .Panels c) and d) exhibit the 
corresponding Scatchard plots of WT and variant R320A/K324A 
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A-2.2 Activation of TAFI variants by plasmin in absence and presence of heparin 
 
In respect to TAFI variants R15A, K59A, S316A, and S249A/S251A, preliminary 
results show that there is an effect of heparin on plasmin mediated activation of TAFI. 
Figure A-2 shows that all of the variants in question displayed increased activation of 
TAFI in the presence of heparin. However, whether or not the effect of heparin on 
activation of these variants is the same or reduced when compared to wild-type cannot be 
concluded using these data, as apparent kcat and Km values cannot be derived with the 
same confidence from these single experiments. Due to the nature of the experiment, and 
the dependency on the standard curve, the reduced rates of activation for some of these 
variants may not be representative of the actual activation kinetics, but rather an artifact 
of a single experiment. Therefore, the activation data cannot be compared between 
variants.. These data can only be used to suggest that mutation of these residues does not 
abolish heparin’s effect on plasmin-mediated activation of TAFI.  
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Figure A-2 Plasmin-mediated activation of TAFI variants in presence and absence 
of heparin. Variants S249A/S251A(a), S316A(b), K59A(c), and R15A(d) were incubated 
with 25 nM plasmin, in the presence (circle) or absence (cross) of 0.02 U/µL heparin for 
12 minutes at room temperature. Results are representative of one experiment. 
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A-2.3 Thermal stability of TAFI variants in the presence and absence of heparin 
Contribution of serine 316, serine 249, and serine 251 on the stability of TAFI in the 
presence and absence of heparin was estimated using a thermal stability assay. Figure A-3 
and table A-1 display that there is a clear difference in the thermal stability of these 
variants in the presence and absence of heparin. From these preliminary results it can be 
concluded that mutation of these residues did not abolish the effect of heparin on thermal 
stability. However, since these experiments were only done once, it cannot be concluded 
if effect of heparin on the stability of these variants is reduced, or the same when 
compared to wild-type. 
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Figure A-3 Intrinsic stability of TAFIa variants in the absence and presence of 
heparin at 37˚C. Variants S316A and S249A were activated in the presence of thrombin-
TM, and incubated at 37˚C in the presence (circle) or absence (cross) of heparin. TAFIa 
activity was measured at different time points. The data were fit to the equation 
describing first-order exponential decay in order to determine the half-lives of TAFIa 
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Table A-1  Intrinsic stability of TAFIa variants in the absence and presence of 
heparin at 37˚C.  
Decay constants estimated by the regression of the data in Fig. A-3 were used to calculate 
the half-lives of the TAFIa mutant in the absence and presence of heparin. 
 
Variant Half-life n 
 + heparin (min) -heparin (min) 
S316A 14.2 
 
 
10.1 1 
S249A/S251A 11.7 
 
 
7.2 1 
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